(86) Date de dépôt PCT/PCT Filing Date: 2005/05/30
(87) Date publication PCT/PCT Publication Date: 2005/12/08
(85) Entrée phase nationale/National Entry: 2006/11/29
(86) N° demande PCT/PCT Application No.: EP 2005/005882
(87) N° publication PCT/PCT Publication No.: 2005/116001
(30) Priorités/Priorities: 2004/05/29 (GB0412198.4); 2004/06/24 (GB0414194.1); 2004/10/29 (GB0424016.4)
(51) Cl.Int./Int.Cl. C07D 277/30 (2006.01), A61K 31/426 (2006.01), A61K 31/427 (2006.01), A61P 11/06 (2006.01), C07D 417/04 (2006.01), C07D 417/06 (2006.01)
(71) Demandeur/Applicant: 7TM PHARMA A/S, DK
(72) Inventeurs/Inventors: ULVEN, TROND, DK; FRIMURER, THOMAS, DK; RIST, OYEISTEIN, DK; KOSTENIS, EVE, DK; HOEGBERG, THOMAS, DK; RECEVEUR, JEAN-MARIE, DK; GRIMSTRUP, MARIE, DK

(54) Titre : ACIDES THIAZOLEACETIQUES SUBSTITUES EN TANT QUE LIGANDS CRTH2
(54) Title: SUBSTITUTED THIAZOLEACETIC AS CRTH2 LIGANDS

(57) Abrégé/Abstract:
Compounds of formula (I) are useful for the treatment of disease responsive to modulation of CRTH2 receptor activity, such as asthma, rhinitis, allergic airway syndrome, and allergic rhinobronchitis; wherein X is -S-, -O-, -N=N-, -NR-, -CR=CR-, -CR=N-, wherein R and R are independently hydrogen or C1-C alkyl; A is a carboxyl group -COOH, or a carboxyl bioisostere; rings Ar and Ar each independently represent a phenyl or 5- or 6-membered monocyclic heteroaryl ring, or a bicyclic ring system consisting of a 5- or 6-membered carbocyclic or heterocyclic ring which is benz-fused or fused to a 5- or 6-membered monocyclic heteroaryl ring, said ring or ring system being optionally substituted; ring B is as defined for Ar and Ar, or an optionally substituted N-pyrrolidinyl, N-piperidinyl or N-azepinyl ring; s is 0 or 1; L1, L2 and L4 are linker radicals as defined in the description; Q1 and Q2 represent substituents as defined in the description.
Agent: GOWLING LA FLEUR HENDERSON LLP

(21) International Application Number: PCT/EP2005/005882

(22) International Filing Date: 30 May 2005 (30.05.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0412198.4 29 May 2004 (29.05.2004) GB
0414194.1 24 June 2004 (24.06.2004) GB
0424016.4 29 October 2004 (29.10.2004) GB


(72) Inventors; and


(57) Abstract: Compounds of formula (I) are useful for the treatment of disease responsive to modulation of CRTH2 receptor activity, such as asthma, rhinitis, allergic airway syndrome, and allergic rhinobronchitis; wherein X1 is -SO2-, -SO3-, -N=-, -NRZ-, -CR=CR2-, -CR=R', wherein R1 and R4 are independently hydrogen or C1-C4 alkyl; A is a carbonyl group -COOH, or a carbonyl bioisostere; rings Ar2 and Ar3 each independently represent a phenyl or 5- or 6-membered monocyclic heteroaryl ring, or a bicyclic ring system consisting of a 5- or 6-membered carbocyclic or heterocyclic ring which is benz-fused or fused to a 5- or 6-membered monocyclic heterocarly ring, said ring or ring system being optionally substituted; ring B is as defined for Ar2 and Ar3, or an optionally substituted N-pyrolidinyl, N-piperidinyl or N-azepinyl ring; s is 0 or 1; L1, L2 and L4 are linker radicals as defined in the description; Q, and Q2 represent substituents as defined in the description.

(54) Title: SUBSTITUTED THIAZOLES ACETIC AS CRTH2 LIGANDS
SUBSTITUTED THIAZOLEACETIC ACIDS AS CRTH2 LIGANDS

This invention relates to a class of compounds which are ligands of the CRTH2 receptor (Chemoattractant Receptor-homologous molecule expressed on T Helper cells type 2), and their use in the treatment of diseases responsive to modulation of CRTH2 receptor activity, principally diseases having a significant inflammatory component. The invention also relates to novel members of that class of ligands and pharmaceutical compositions containing them.

Background to the Invention
The natural ligand of the G-protein coupled receptor CRTH2 is prostaglandin D2. As its name implies, CRTH2 is expressed on T helper cells type 2 (TH2 cells) but it is also known to be expressed on eosinophils and basophil cells. Cell activation as a result of binding of PGD2 to the CRTH2 receptor results in a complex biological response, including release of inflammatory mediators. Elevated levels of PGD2 are therefore associated with many diseases which have a strong inflammatory component, such as asthma, rhinitis and allergies. Blocking binding of PGD2 to the CRTH2 receptor is therefore a useful therapeutic strategy for treatment of such diseases.

Some small molecule ligands of CRTH2, apparently acting as antagonists of PGD2, are known, for example as proposed in the following patent publications: WO 03/097042, WO 03/097598, WO 03/066046, WO 03/066047, WO 03/101961, WO 03/101981, GB 2388540, WO 04/089885 and WO 05/018529.

**Brief Description of the Invention**

The structures of the PGD2 antagonist compounds referred to in the foregoing publications have a bicyclic or tricyclic core ring system related to the indole core of indomethacin, a known anti-inflammatory agent, now known to bind to CRTH2. The present invention arises from the identification of a class of compounds having a 5- or 6-membered nitrogen-containing monocyclic core such as a thiazole ring, whose substituent moieties are orientated by the monocyclic core, to interact with and bind to CRTH2. The class of compounds with which this invention is concerned are thus capable of modulating CRTH2 activity, and are useful in the treatment of diseases which benefit from such modulation, for example asthma, allergy and rhinitis.

**Detailed Description of the Invention**

According to the present invention, there is provided a compound of formula (I) or a salt, hydrate or solvate thereof:

![Chemical Structure](image)

wherein

- X₁ is -S-, -O-, -N=N-, -NR₇-, -CR₇=CR₈-, -CR₇=N-, wherein R₇ and R₈ are independently hydrogen or C₁-C₃ alkyl;

- A is a carboxyl group –COOH, or a carboxyl bioisostere;

- rings Ar² and Ar³ each independently represent a phenyl or 5- or 6-membered monocyclic heteroaryl ring, or a bicyclic ring system consisting of a 5- or 6-membered carbocyclic or heterocyclic ring which is benz-fused or fused to a 5- or 6-membered monocyclic heteroaryl ring, said ring or ring system being optionally substituted;

- ring B is as defined for Ar² and Ar³, or an optionally substituted N-pyrrolidinyl, N-piperidinyl or N-azepinyl ring;
s is 0 or 1;

**L1** represents a divalent radical of formula \(-(\text{Alk}^1)_{m^*}\) and **L2** and **L4** each independently represents a divalent radical of formula \(-(\text{Alk}^1)_{m^*}(\text{Z})_{n^*}(\text{Alk}^2)_{p^*}\) wherein

\(m, n\) and \(p\) are independently 0 or 1,

\(\text{Alk}^1\) and \(\text{Alk}^2\) are independently optionally substituted straight or branched chain \(C_1-C_3\) alkylene or \(C_2-C_3\) alkenylene radicals which may contain a compatible \(-O-, -S-\) or \(-NR-\) link wherein \(R\) is hydrogen or \(C_1-C_3\) alkyl, and

\(Z\) is \(-O-, -S-, -C(=O)-, -SO_2-, -SO-, -NR-, -NRSO_2-, -C(=O)NR-, -NRCONH-,\)

\(\text{NR}(=\text{NR})\text{NH}-, \text{or} =\text{N}-\text{NR-\ wherein R is hydrogen or C}_1\text{-C}_3\text{ alkyl; or a divalent 5- or 6-membered monocyclic carbocyclic or heterocyclic radical; }\)

**L3** represents a divalent radical of formula \(-(\text{Alk}^3)_{m^*}(\text{Z})_{n^*}(\text{Alk}^2)_{p^*}\) wherein \(m, n, p, \text{Alk}^2\) and \(Z\) are as defined in relation to **L2** and **L4**, and **L3** is an optionally substituted straight or branched chain \(C_1-C_2\) alkylene or \(C_1-C_2\) alkenylene radical which may contain a compatible \(-O-, -S-\) or \(-NR-\) link wherein \(R\) is hydrogen or \(C_1-C_3\) alkyl;

\(Q_1\) represents hydrogen or \((C_1-C_6)\text{alkyl};\)

\(Q_2\) represents

(i) \((C_1-C_6)\text{alkyl, (C}_1\text{-C}_6\text{)alkoxy, hydroxy, hydroxy}(C_1-C_6)\text{alkyl, nitrile (-CN), phenyl, phenoxy, monocyclic heteroaryl or heteroaryloxy with 5 or 6 ring atoms, -CONR^A\text{R}^B, -NR^A\text{COR}^A, -NR^B\text{SO}_2\text{R}^A\text{ or} -NR^B\text{CONR}^A\text{R}^B\text{ wherein R}^A\text{ and R}^B\text{ are independently hydrogen or a (C}_1\text{-C}_6\text{)alkyl group, or R}^A\text{ and R}^B\text{ are linked to the same N atom to form a cyclic amino ring, and when Q is phenyl, phenoxy or monocyclic heteroaryl or heteroaryloxy with 5 or 6 ring atoms the phenyl or heteroaryl ring is optionally substituted by any of (C}_1\text{-C}_6\text{)alkyl, (C}_1\text{-C}_6\text{)alkoxy, hydroxy, hydroxy}(C_1-C_6)\text{alkyl, (C}_1\text{-C}_3\text{)alkylthio, halo, fully or partially fluorinated (C}_1\text{-C}_3\text{)alkyl, (C}_1\text{-C}_3\text{)alkoxy or (C}_1\text{-C}_3\text{)alkylthio, trifluoromethylthio, nitro, nitrile (-CN), COOR}^A, -COR^A, -OCOR^A, -SO_2R^A, -CONR^A\text{R}^B, -SO_2\text{NR}^B\text{R}^B, -NR^B\text{R}^B, -NR^B\text{COR}^A, -NR^B\text{COOR}^A, -NR^B\text{SO}_2\text{R}^A\text{ or} -NR^B\text{CONR}^A\text{R}^B\text{ wherein R}^A\text{ and R}^B\text{ are independently hydrogen or a (C}_1\text{-C}_6\text{)alkyl group, or R}^A\text{ and R}^B\text{ are linked to the same N atom to form a cyclic amino ring, or}

\(3\)
(ii) hydrogen, but only when, in L3, Z represents an optionally substituted divalent 5- or 6-membered monocyclic carbocyclic or heterocyclic radical;

or Q₁ and Q₂ taken together with the carbon atom to which they are attached form a C₃-C₆ cycloalkyl ring or a monocyclic non-aromatic heterocyclic ring with 4-6 ring atoms;

and wherein the total length of L2 and L3 does not exceed that of an unbranched saturated chain of 10 carbon atoms.

In a narrower definition of the compounds (I), (i) the length of each of L2, L3 and L4 does not exceed that of an unbranched saturated chain of 5 atoms and (ii) the total length of L2, L3 and L4 does not exceed that of an unbranched saturated chain of 7 atoms, and (iii) none of L1, L2, L3 and L4 includes more than two R substituents different from hydrogen.

The compounds with which the invention is concerned are defined by reference to formula (I) as a result of studies towards elucidation of the ligand binding site of CRTH2. Such studies led to the overall conclusion that a general pharmacophore comprising one negatively charged moiety, represented by AL₁-, and two aromatic and/or hydrophobic moieties, represented by H(B)ₓL₄Ar²L₂ and either the ring containing X₁ or the ring containing X₁, together with the H(Aₓ)₃L₃C(Q₁)(Q₂)- fragment, oriented in an approximate triangle, would form an arrangement for interaction with the receptor binding site. It was concluded that the substituent groupings AL₁-, H(B)ₓL₄Ar²L₂- should be on adjacent ring atoms of the ring containing X₁. The linkers L₁, L₂, L₃ and L₄ provide some flexibility to the molecule to facilitate optimum binding. The restrictions on the lengths of, and and substitutions in, the linkers L₂, L₃ and L₄ are in order to restrict the total molecular size and complexity of structures for use in accordance with the invention. For the avoidance of doubt, the total length of L₂ and L₃ is, for the purposes of this description and claims, the sum n₂+n₃, where n₂ is the number of connected atoms in the shortest chain of atoms from terminal atom to terminal atom of linker L₂, and n₃ is the number of connected atoms in the shortest chain of atoms from terminal atom to terminal atom of linker L₂. Preferably the compounds with which the invention is concerned should have a molecular weight of no more than 600. Optional substituents in any element of the compounds (I) are permitted as in the definition of compounds (I). Such substituents can
modulate pharmacokinetic and solubility properties, as well as picking up additional binding interactions with the receptor.

In another aspect, the invention provides the use of a compound as defined and discussed herein in the manufacture of a composition for the treatment of disease responsive to modulation of CRTH2 receptor activity.

In another aspect, the invention provides a method of treatment of a subject suffering from a disease responsive to modulation of CRTH2 receptor activity, which comprised administering to the subject an amount of a compound (I) as defined and discussed herein, effective to ameliorate the disease.

In particular, compounds with which the invention is concerned are useful in the treatment of disease associated with elevated levels of prostaglandin D2 (PGD2) or one or more active metabolites thereof.

Examples of such diseases include asthma, rhinitis, allergic airway syndrome, allergic rhinobronchitis, bronchitis, chronic obstructive pulmonary disease (COPD), nasal polyposis, sarcoidosis, farmer’s lung, fibroid lung, cystic fibrosis, chronic cough, conjunctivitis, atopic dermatitis, Alzheimer’s disease, amyotrophic lateral sclerosis, AIDS dementia complex, Huntington’s disease, frontotemporal dementia, Lewy body dementia, vascular dementia, Guillain-Barre syndrome, chronic demyelinating polyradiculoneuropathy, multifocal motor neuropathy, plexopathy, multiple sclerosis, encephalomyelitis, panencephalitis, cerebellar degeneration and encephalomyelitis, CNS trauma, migraine, stroke, rheumatoid arthritis, ankylosing spondylitis, Behçet’s Disease, bursitis, carpal tunnel syndrome, inflammatory bowel disease, Crohn’s disease, ulcerative colitis, dermatomyositis, Ehlers-Danlos Syndrome (EDS), fibromyalgia, myofascial pain, osteoarthritis (OA), osteonecrosis, psoriatic arthritis, Reiter’s syndrome (reactive arthritis), sarcoidosis, scleroderma, Sjogren’s Syndrome, soft tissue disease, Still’s Disease, tendinitis, polyarthritis nodosa, Wegener’s Granulomatosis, myositis (polymyositis dermatomyositis), gout, atherosclerosis, lupus erythematosus, systemic lupus erythematosus (SLE), type 1 diabetes, nephritic syndrome, glomerulonephritis, acute and chronic renal failure, eosinophilia fascitis, hyper IgE syndrome, sepsis, septic shock, ischemic reperfusion injury in the heart, allograft rejection after transplantations, and graft versus host disease.
However, the compounds with which the invention is concerned are primarily of value for the treatment asthma, rhinitis, allergic airway syndrome, and allergic rhinobronchitis.

As used herein, the term "(Cₐ-C₆)alkyl" wherein a and b are integers refers to a straight or branched chain alkyl radical having from a to b carbon atoms. Thus when a is 1 and b is 6, for example, the term includes methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl and n-hexyl.

As used herein the term "divalent (Cₐ-C₆)alkylene radical" wherein a and b are integers refers to a saturated hydrocarbon chain having from a to b carbon atoms and two unsatisfied valences.

As used herein the term "(Cₐ-C₆)alkenyl" wherein a and b are integers refers to a straight or branched chain alkenyl moiety having from a to b carbon atoms having at least one double bond of either E or Z stereochemistry where applicable. The term includes, for example, vinyl, allyl, 1- and 2-butenyl and 2-methyl-2-propenyl.

As used herein the term "divalent (Cₐ-C₆)alkenylene radical" means a hydrocarbon chain having from a to a carbon atoms, at least one double bond, and two unsatisfied valences.

As used herein the term "Cₐ-C₆ alkynyl" wherein a and b are integers refers to straight chain or branched chain hydrocarbon groups having from two to six carbon atoms and having in addition one triple bond. This term would include for example, ethynyl, 1- and 2-propynyl, 1-, 2- and 3-butylnyl, 1, 2-, 3- and 4-pentylnyl, 1-, 2-, 3-, 4- and 5-hexynyl, 3-methyl-1-butylnyl, 1-methyl-2-pentylnyl.

As used herein the term "divalent (Cₐ-C₆)alkynylene radical" wherein a and b are integers refers to a divalent hydrocarbon chain having from 2 to 6 carbon atoms, at least one triple bond, and two unsatisfied valences.

As used herein the term "carbocyclic" refers to a mono-, bi- or tricyclic radical having up to 16 ring atoms, all of which are carbon, and includes aryl and cycloalkyl.
As used herein the term "cycloalkyl" refers to a monocyclic saturated carbocyclic radical having from 3-8 carbon atoms and includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.

As used herein the unqualified term "aryl" refers to a mono-, bi- or tri-cyclic carbocyclic aromatic radical, and includes radicals having two monocyclic carbocyclic aromatic rings which are directly linked by a covalent bond. Illustrative of such radicals are phenyl, biphenyl and napthyl.

As used herein the unqualified term "heteroaryl" refers to a mono-, bi- or tri-cyclic aromatic radical containing one or more heteroatoms selected from S, N and O, and includes radicals having two such monocyclic rings, or one such monocyclic ring and one monocyclic aryl ring, which are directly linked by a covalent bond. Illustrative of such radicals are thiényl, benzthienyl, furyl, benzfuryl, pyrrolyl, imidazolyl, benzimidazolyl, thiazolyl, benzthiazolyl, isothiazolyl, benzisothiazolyl, pyrazolyl, oxazolyl, benzoxazolyl, isoxazolyl, benzisoxazolyl, triazolyl, benztriazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyridazinyl, triazinyl, indolyl and indazolyl.

As used herein the unqualified term "heterocyclyl" or "heterocyclic" includes "heteroaryl" as defined above, and in addition means a mono-, bi- or tri-cyclic non-aromatic radical containing one or more heteroatoms selected from S, N and O, and to groups consisting of a monocyclic non-aromatic radical containing one or more such heteroatoms which is covalently linked to another such radical or to a monocyclic carbocyclic radical. Illustrative of such radicals are pyrrolyl, furanyl, thiényl, piperidinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, pyrazolyl, pyridinyl, pyrroldinyl, pyrimidinyl, morpholinyl, piperazinyl, indolyl, morpholinyll, benzfuranyl, pyranly, isoxazolyl, benzimidazolyl, methylenedioxophenyl, ethylenedioxophenyl, maleimido and succinimido groups.

The term "carboxyl bioisostere" is a term familiar to medicinal chemists (see for example "The Organic Chemistry of Drug Design and Drug Action", by Richard B. Silverman, pub. Academic Press, 1992), and refers to a group which has similar acid-base characteristics to those of a carboxyl group. Well known carboxyl bioisosteres include -SO₂NHR or -P(=O)(OH)(OR) wherein R is, for example, hydrogen methyl or ethyl, -SO₂OH, -P(=O)(OH)(NH₂), -C(=O)NHCN and groups of formulae:
Unless otherwise specified in the context in which it occurs, the term "substituted" as applied to any moiety herein means substituted with up to four compatible substituents, each of which independently may be, for example, (C1-C8)alkyl, (C1-C8)alkoxy, hydroxy, hydroxy(C1-C8)alkyl, mercapto, mercapto(C1-C8)alkyl, (C1-C8)alkythio, halo (including fluoro, bromo and chloro), fully or partially fluorinated (C1-C8)alkyl, (C1-C8)alkoxy or (C1-C8)alkythio such as trifluoromethyl, trifluoromethoxy, and trifluoromethylthio, nitro, nitrite (-CN), oxo, phenyl, phenoxy, monocyclic heteroaryl or heteroaryloxy with 5 or 6 ring atoms, -COOR\(^A\), -COR\(^A\), -OCOR\(^A\), -SO\(_2\)R\(^A\), -CONR\(^A\)R\(^B\), -SO\(_2\)NR\(^A\)R\(^B\), -NR\(^A\)R\(^B\), OCONR\(^A\)R\(^B\), -NR\(^B\)COR\(^A\), -NR\(^B\)COOR\(^A\), -NR\(^B\)SO\(_2\)OR\(^A\) or -NR\(^A\)CONR\(^A\)R\(^B\) wherein R\(^A\) and R\(^B\) are independently hydrogen or a (C1-C8)alkyl group or, in the case where R\(^A\) and R\(^B\) are linked to the same N atom, R\(^A\) and R\(^B\) taken together with that nitrogen may form a cyclic amino ring. Where the substituent is phenyl, phenoxy or monocyclic heteroaryl or heteroaryloxy with 5 or 6 ring atoms, the phenyl or heteroaryl ring thereof may itself be substituted by any of the above substituents except phenyl phenoxy, heteroaryl or heteroaryloxy. An "optional substituent" may be one of the foregoing substituent groups.

As used herein the term "salt" includes base addition, acid addition and quaternary salts. Compounds of the invention which are acidic can form salts, including pharmaceutically acceptable salts, with bases such as alkali metal hydroxides, e.g. sodium and potassium hydroxides; alkaline earth metal hydroxides e.g. calcium, barium and magnesium hydroxides; with organic bases e.g. N-methyl-D-glucamine, choline tris(hydroxymethyl)amino-methane, L-arginine, L-lysine, N-ethyl piperidine, dibenzylamine and the like. Those compounds (I) which are basic can form salts, including pharmaceutically acceptable salts with inorganic acids, e.g. with hydrohalic acids such as hydrochloric or hydrobromic acids, sulphuric acid, nitric acid or phosphoric acid and the like, and with organic acids e.g. with acetic, tartaric, succinic, fumaric, maleic, malic, salicylic, citric, methanesulphonic, p-toluenesulphonic, benzoic, benzenesulphonic, glutamic, lactic, and mandelic acids and the like.
Compounds with which the invention is concerned which may exist in one or more stereoisomeric form, because of the presence of asymmetric atoms or rotational restrictions, can exist as a number of stereoisomers with R or S stereochemistry at each chiral centre or as atropisomers with R or S stereochemistry at each chiral axis. The invention includes all such enantiomers and diastereoisomers and mixtures thereof.

Use of prodrugs, such as esters, of compounds (I) with which the invention is concerned is also part of the invention.

For use in accordance with the invention, the following structural characteristics are currently preferred, in any compatible combination, in the compounds (I):

Q₁ is hydrogen, and Q₂ is phenyl or monocyclic heteroaryl with 5 or 6 ring atoms optionally substituted by any of (C₁-C₉)alkyl, (C₁-C₉)alkoxy, hydroxy, hydroxy(C₁-C₉)alkyl, (C₁-C₃)alkylthio, halo, fully or partially fluorinated (C₁-C₃)alkyl, (C₁-C₃)alkoxy or (C₁-C₃)alkylthio, trifluoromethylthio, nitro, nitrile (-CN), -COOR₆, -COR₆, -OCOR₆, -SO₂R₆, -CONR₆R₆, -SO₂NR₆R₆, -NR₆R₆, -NR₆COR₆, -CONR₆R₆, -NR₆SO₂OR₆ or -NR₆CONR₆R₆ wherein R₆ and R₆ are independently hydrogen or a (C₁-C₉)alkyl group, or R₆ and R₆ are linked to the same N atom to form a cyclic amino ring; or

Q₁ is hydrogen, and Q₂ is phenyl, optionally substituted by any of fluoro, chloro, bromo, (C₁-C₃)alkyl, trifluoromethyl, (C₁-C₃)alkoxy, trifluoromethoxy, trifluoromethylthio, dimethylamino, cyano, (C₁-C₉alkyl)SO₂, NH₂SO₂, (C₁-C₃alkyl)OH, (C₁-C₃alkyl)NH₂, (C₁-C₃alkyl)NH₂SO₂, -CONR₆R₆, and -NR₆COR₆ wherein R₆ and R₆ are independently hydrogen or a (C₁-C₉)alkyl group, or R₆ and R₆ are linked to the same N atom to form a cyclic amino ring.

L₃ is -CH₂, -O-, -S-, -SO₂-, -NHC(O)-, -CH=CH-, -NR₁₁-, or -NR₁₁CH₂-, wherein R₁₁ is hydrogen or C₁-C₃ alkyl; or

L₃ represents a divalent radical of formula -(Alk³)n(Z)n(Alk³)p wherein m is 0, n is 1, and Z is a phenylene radical optionally substituted by one or more of fluoro, chloro, bromo, (C₁-C₃)alkyl, trifluoromethyl, (C₁-C₃)alkoxy, trifluoromethoxy, trifluoromethylthio, dimethylamino, cyano, (C₁-C₉alkyl)SO₂, NH₂SO₂, (C₁-C₉alkyl)NH₂SO₂, (C₁-C₉alkyl)NH₂, -CONR₆R₆, and -
NR^6COR^8, wherein R^A and R^B are independently hydrogen or a (C_1-C_6) alkyl group, or R^A and R^B are linked to the same N atom to form a cyclic amino ring. In these cases, Z may be, for example, a 1, 2-phenylene radical optionally substituted by one or more of fluoro, chloro, bromo, (C_1-C_3) alkyl, trifluoromethyl, (C_1-C_3) alkoxy, trifluoromethoxy, trifluoromethylthio, dimethylamino, cyano, (C_1-C_3 alkyl)SO_2^-, NH_2SO_2^-, (C_1-C_3 alkyl)NHSO_2^-, (C_1-C_3 alkyl)_2NSO_2^-, -CONR^A^B^8, and -NR^8COR^A wherein R^A and R^B are independently hydrogen or a (C_1-C_6) alkyl group, or R^A and R^B are linked to the same N atom to form a cyclic amino ring.

In particular, Q_1 may be hydrogen, X_1 may be -S-, and A is may be carboxyl group -COOH;

L1 is a bond, -CR_1 R_12^-, -CH_2 CR_1 R_12^-, -OCR_1 R_12^-, -SCR_1 R_12^-, 
*NR_11 CH_2^- or -NR_11^- wherein R_11 and R_12 are independently hydrogen or C_1 - C_3 alkyl, the bond marked with an asterisk being the one connected to the ring containing X^1. For example L1 may be -CH_2^- or -CH(CH_3)^-.

Ar^3 is phenyl, thienyl, naphthyl or 2-, 3- or 4-pyridyl, any of which is optionally substituted, for example by one or more substituents selected from fluoro, chloro, bromo, (C_1-C_3) alkyl, trifluoromethyl, (C_1-C_3) alkoxy, trifluoromethoxy, trifluoromethylthio, dimethylamino, cyano, (C_1-C_3 alkyl)SO_2^-, NH_2SO_2^-, (C_1-C_3 alkyl)NHSO_2^-, (C_1-C_3 alkyl)_2NSO_2^-, -CONR^A^B^8, and -NR^8COR^A wherein R^A and R^B are independently hydrogen or a (C_1-C_6) alkyl group, or R^A and R^B are linked to the same N atom to form a cyclic amino ring;

L2 is a bond and Ar^2 is an optionally substituted phenyl, thienyl, furanyl, pyrrolyl or pyridyl ring, optional substituents being selected from fluoro, chloro, bromo, (C_1-C_3) alkyl, trifluoromethyl, (C_1-C_3) alkoxy, trifluoromethoxy, trifluoromethylthio, dimethylamino, cyano, (C_1-C_3 alkyl)SO_2^-, NH_2SO_2^-, (C_1-C_3 alkyl)NHSO_2^-, (C_1-C_3 alkyl)_2NSO_2^-, -CONR^A^B^8, and -NR^8COR^A wherein R^A and R^B are independently hydrogen or a (C_1-C_6) alkyl group, or R^A and R^B are linked to the same N atom to form a cyclic amino ring;

s is 0.
One preferred subclass of the compounds with which the invention is concerned consists of compounds of formula (IA), and salts, hydrates and solvates thereof:

wherein $A_1$ is hydrogen or methyl, $X_1$, $Q_1$, $Ar^3$ and $L3$ are as defined and discussed above, and $R_4$ and $R_5$ independently represent hydrogen or one or more optional substituents. In this subclass, it is currently preferred that

- $A_1$ is hydrogen,
- $Q_1$ is hydrogen,
- $X_1$ is $-S-$,
- $Ar^3$ is optionally substituted phenyl,
- $L3$ is a bond, $-O-$, $-S-$, or $-NR-$ wherein $R$ is hydrogen or C$_1$-C$_3$ alkyl.

Particularly preferred in this subclass are compounds (IA) wherein $A_1$ is hydrogen, $Q_1$ is hydrogen, $X_1$ is $-S-$, $Ar^3$ is optionally substituted phenyl and $L3$ is a bond.

In this subclass, optional substituents $R_4$ and $R_5$ and optional substituents in $Ar^3$ are preferably independently selected from fluoro, chloro, bromo, (C$_1$-C$_3$)alkyl, trifluoromethyl, (C$_1$-C$_3$)alkoxy, trifluoromethoxy, trifluoromethylthio, dimethylamino, cyano, (C$_1$-C$_3$)alkyl)SO$_2$-, NH$_2$SO$_2$-, (C$_1$-C$_3$)alkyl)NHSO$_2$-, (C$_1$-C$_3$)alkyl)$_2$NSO$_2$-, -CONR$_4^A$R$_8^B$, and -NR$_4^A$COR$_8^B$ wherein $R^A$ and $R^B$ are independently hydrogen or a (C$_1$-C$_6$)alkyl group, or $R^A$ and $R^B$ are linked to the same $N$ atom to form a cyclic amino ring.

One preferred subclass of the compounds with which the invention is concerned consists of compounds of formula (IA), and salts, hydrates and solvates thereof:
wherein A₁ is hydrogen or methyl, X₂ is a bond, −CH₂−, −O−, −S−, or −NR− wherein R is hydrogen or C₁-C₃ alkyl and X₁ and Ar³ are as defined in claim 1, and R₄ and R₅ independently represent hydrogen or one or more optional substituents. In this subclass, it is currently preferred that

- A₁ is hydrogen,
- X₁ is −S−,
- Ar³ is optionally substituted phenyl,
- X₂ is −CH₂− or a bond.

In this subclass, optional substituents R₄ and R₅, and optional substituents in Ar³ are independently selected from fluoro, chloro, bromo, (C₁-C₃)alkyl, trifluoromethyl, (C₁-C₃)alkoxy, trifluoromethoxy, trifluoromethylthio, dimethylamino, cyano, (C₁-C₅alkyl)SO₂−, NH₂SO₂− (C₁-C₅alkyl)NH₂SO₂−, (C₁-C₅alkyl)₂NSO₂−, -CONRA⁴R⁸, and -NR⁶COR⁴ wherein R⁶ and R⁸ are independently hydrogen or a (C₁-C₅)alkyl group, or R⁶ and R⁸ are linked to the same N atom to form a cyclic amino ring.

Specific examples of compounds with which the invention is concerned include:

- [2-benzhydryl-4-(4-chlorophenyl)-thiazol-5-yl]-acetic acid,
- [2-benzhydryl-4-(4-fluoro-phenyl)-thiazol-5-yl]-acetic acid,
- [2-{1-(4-chloro-phenyl)-2-phenyl-ethyl}-4-(4-fluoro-phenyl)-thiazol-5-yl]-acetic acid,
- [4-(4-chloro-phenyl)-2-[(4-chloro-phenyl)-phenyl-methyl]-thiazol-5-yl]-acetic acid,
- [2-[[4-chloro-phenyl]-phenyl-methyl]-4-(4-fluoro-phenyl)-thiazol-5-yl]-acetic acid,
- [2-[bis-(4-fluoro-phenyl)-methyl]-4-(4-fluoro-phenyl)-thiazol-5-yl]-acetic acid,
- [4-(4-fluoro-phenyl)-2-[(4-methoxy-phenyl)-phenyl-methyl]-thiazol-5-yl]-acetic acid,
- [4-(4-chloro-phenyl)-2-[(4-methoxy-phenyl)-phenyl-methyl]-thiazol-5-yl]-acetic acid,
- [2-[[3,4-difluoro-phenyl]-phenyl-methyl]-4-(4-fluoro-phenyl)-thiazol-5-yl]-acetic acid,
- [2-[bis-(4-methoxy-phenyl)-methyl]-4-(4-fluoro-phenyl)-thiazol-5-yl]-acetic acid,
[2-benzhydryl-4-(3-fluoro-phenyl)-thiazol-5-yl]-acetic acid,
[2-[bis-(4-fluoro-phenyl)-methyl]-4-(3,4-difluoro-phenyl)-thiazol-5-yl]-acetic acid,
[2-benzhydryl-4-(3,4-difluoro-phenyl)-thiazol-5-yl]-acetic acid,
[2-[bis-(4-fluoro-phenyl)-methyl]-4-(3-fluoro-phenyl)-thiazol-5-yl]-acetic acid,

and salts hydrates and solvates thereof.

The invention also includes pharmaceutical compositions comprising a compound formula (II) or (IIA) together with a pharmaceutically acceptable carrier.

**Compositions**

As mentioned above, the compounds with which the invention is concerned are capable of modulating CRTH2 activity, and are useful in the treatment of diseases which benefit from such modulation. Examples of such diseases are referred to above, and include asthma, rhinitis, allergic airway syndrome, and allergic rhinobronchitis.

It will be understood that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing treatment. Optimum dose levels and frequency of dosing will be determined by clinical trial, as is required in the pharmaceutical art.

The compounds with which the invention is concerned may be prepared for administration by any route consistent with their pharmacokinetic properties. The orally administrable compositions may be in the form of tablets, capsules, powders, granules, lozenges, liquid or gel preparations, such as oral, topical, or sterile parenteral solutions or suspensions. Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinyl-pyrrolidone; fillers for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tableting lubricant, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants for example potato starch, or acceptable wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in normal pharmaceutical practice. Oral
liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, glucose syrup, gelatin hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.

For topical application to the skin, the drug may be made up into a cream, lotion or ointment. Cream or ointment formulations which may be used for the drug are conventional formulations well known in the art, for example as described in standard textbooks of pharmaceutics such as the British Pharmacopoeia.

For topical application to the eye, the drug may be made up into a solution or suspension in a suitable sterile aqueous or non-aqueous vehicle. Additives, for instance buffers such as sodium metabisulphite or disodium edeate; preservatives including bactericidal and fungicidal agents such as phenyl mercuric acetate or nitrate, benzalkonium chloride or chlorhexidine, and thickening agents such as hypromellose may also be included.

The drug may also be formulated for inhalation, for example as a nasal spray, or dry powder or aerosol inhalers.

The active ingredient may also be administered parenterally in a sterile medium. Depending on the vehicle and concentration used, the drug can either be suspended or dissolved in the vehicle. Advantageously, adjuvants such as a local anaesthetic, preservative and buffering agents can be dissolved in the vehicle.

The compounds with which the invention is concerned may be administered alone, or as part of a combination therapy with other drugs used for treatment of diseases with a major inflammatory component. In the case of asthma, rhinitis, and allergic airway syndrome such drugs include corticosteroids, long-acting inhaled beta-agonists, beta agonists, cromolyn, nedocromil, theophylline, leukotriene receptor antagonists,
antihistamines, and anticholinergics (e.g. ipratropium), and are often administered as nasal sprays, dry powder or aerosol inhalers.

In the case of arthritis and related inflammatory diseases other known drugs include glucocorticoids, NSAIDs (Non Steroidal Anti-Inflammatory Drugs – conventional prostaglandin synthesis inhibitors, COX-2 inhibitors, salicylates), and DMARDs (disease-modifying anti-rheumatic drugs such as methotrexate, sulfasalazine, gold, cyclosporine).

**Synthetic Routes**

There are multiple synthetic strategies for the synthesis of the compounds (I) with which the present invention is concerned, but all rely on known chemistry, known to the synthetic organic chemist. Thus, compounds according to formula (I) can be synthesised according to procedures described in the standard literature and are well-known to the one skilled in the art. Typical literature sources are "*Advanced organic chemistry*, 4th Edition (Wiley), J March, "*Comprehensive Organic Transformation*, 2nd Edition (Wiley), R.C. Larock, "*Handbook of Heterocyclic Chemistry*, 2nd Edition (Pergamon), A.R. Katritzky), review articles such as found in "*Synthesis*, "*Acc. Chem. Res.*", "*Chem. Rev.***, or primary literature sources identified by standard literature searches online or from secondary sources such as "*Chemical Abstracts*" or "*Beilstein*".

In the following discussion of synthetic routes, the ring "Ar1" is the ring shown in formula (I) containing X₁.

The linker L2 can be formed by joining two appropriately functionalised and, if needed, suitably protected fragments containing La2 and Lb2 as reactive moieties as outlined below. La2 and Lb2 are defined as any moieties that can react by e.g. a nucleophilic substitution, addition to multiple bonds or cyclisation reaction to form a given L2 linker as in:
For example, the linker \(-L2\)- being \(-\text{Alk}^1\)-Z-(\text{Alk}^2)_p- can be formed by reacting 
HBL4Ar\(^2\)-Alk\(^1\)-“leaving group” with a nucleophilic derivative H-Z-(\text{Alk}^2)_p-
Ar\(^1\)(L1A)L3Ar\(^3\)H wherein Z could be O, S or NR and \text{Alk}^1 could be an alkyl group. The 
reactions can also be made by reversing the functionalisation of La2 and Lb2 to 
makes the connection between Z and \text{Alk}^2. The linkers having Z being SO or SO\(_2\) can 
be obtained by oxidations of the corresponding \(-(\text{Alk}^1)_m\)-S-(\text{Alk}^2)_p- derivatives during 
appropriate conditions.

Further representative examples, \(-L2\)- being \(-\text{Alk}^1\)-Z-(\text{Alk}^2)_p- wherein Z is NH(CO) or 
NHSO\(_2\) can be formed by reacting HBL4Ar\(^2\)\(-(\text{Alk}^1)\)-NH\(_2\) with an acetyliing derivative 
“leaving group”-CO-(\text{Alk}^2)_p-Ar\(^1\)(L1A)L3Ar\(^3\)H or “leaving group”-SO\(_2\)-(\text{Alk}^2)_p-
Ar\(^1\)(L1A)L3Ar\(^3\)H, respectively. Alternatively, the conversion can be made directly with 
the acids HO-CO-(\text{Alk}^2)_p-Ar\(^1\)(L1A)L3Ar\(^3\)H and HO-SO\(_2\)-(\text{Alk}^2)_p-Ar\(^1\)(L1A)L3Ar\(^3\)H,
respectively, using suitable coupling reagents such as dicyclohexylcarbodiimide 
(DCC), and promoters such as 1-hydroxybenzotriazole. Analogously, \(-L2\)- being 
\(-\text{Alk}^1\)-Z-(\text{Alk}^2)_p- wherein Z being NH(CO)NH can be formed by reacting HBL4Ar\(^2\)-
(\text{Alk}^1)-NH\(_2\) with an isocyanate derivative OCN-(\text{Alk}^2)_p-Ar\(^1\)(L1A)L3Ar\(^3\)H using suitable 
acid or base catalyst. The reactions can also be made by reversing the 
functionalisation of La2 and Lb2 to provide the “retro-bonds” in the case of NH(CO) 
or NHSO\(_2\). Analogously, the connections can be made between Z and \text{Alk}^2.

Likewise, L2 being \(-(\text{Alk}^1)_m\)-Z-(\text{Alk}^2)_p- wherein Z is a 5-membered heterocyclic 
system exemplified by 

![Chemical structures](image)
can be made according to standard cyclisation procedures using appropriate 
solvents, catalysts and temperatures. For example, formation of 1,2,4-triazole can be 
made with La2 being acylhydrazide and Lb2 being amide or thioamide or the reverse 
orientation of La2 and Lb2. 1,2,4-Oxadiazole can be formed from La2 being 
amidoxime and Lb2 being carboxylic ester or the reverse orientation of La2 and Lb2.
1,3,4-Oxadiazole can be formed from La2 being acylhydrazide and Lb2 being carboxylic ester or the reverse orientation of La2 and Lb2. The thiazole can be made from La2 being thioamide and Lb2 being an α-haloketone or the reverse orientation of La2 and Lb2.

In an analogous manner the compounds of formula (I) can be made by forming the linkers L3 or L4, according to procedures outlined for L2, as depicted below. Thus, La and Lb are defined as any moieties that can react by e.g. a nucleophilic substitution, addition to multiple bonds or cyclisation reaction to form a given linker L as exemplified below.

\[
\text{and}
\]

The Ar^1 moiety can also be the central scaffold that is used in connecting the L1, L2 and L3 parts in a stepwise fashion. This can be done via aromatic substitutions of the Ar^1 core to attach L1, L2 and/or L3, which then can be further functionalised to give the final Formula I compounds.

Furthermore, the five-membered X_1-azole moiety can also be assembled via conventional ring cyclisation reactions with reactants containing the L1, L2 and L3 units either containing the full appendices as exemplified below wherein Lg is a leaving group such as halogen,
or in forms that can be further functionalised into the final formula (I) structures as described previously. One such illustration is given below:

For example, 1,2,4-triazoles can be made from acylhydrazides and amides or thioamides; 1,2,4-oxadiazoles from amidoximes and carboxylic esters; 1,3,4-oxadiazoles from acylhydrazides and carboxylic esters; thiazoles from thioamides and α-haloketones; pyrazines, pyrimidines and pyridines via various condensation and cycloaddition reactions.


The Examples herein describe specific strategies for the synthesis of compounds (I) wherein X1 is S.
The following Examples illustrate the preparation of compounds with which this invention is concerned. Some compounds were synthesised, and some were acquired from commercial sources. In the Examples:

**General comments:**

NMR spectra were obtained on a Bruker Avance AMX 300 MHz instrument. For some compounds only selected characteristic $^1$H NMR signals are reported. LC/MS was performed on an Agilent 1100-series instrument. LC/MS methods are as follows: **An10p8**: Column: XTerra MS C18; Flow: 1.0 mL/min; Gradient: 0-5 min: 15-100% MeCN in water, 5-7½ min: 100% MeCN; Modifier: 5 mM ammonium formate; MS-ionisation mode: API-ES (pos.). **An10n8**: Column: XTerra MS C18; Flow: 1.0 mL/min; Gradient: 0-5 min: 15-100% MeCN in water, 5-7½ min: 100% MeCN; Modifier: 5 mM ammonium formate; MS-ionisation mode: API-ES (neg.).

**General synthetic route I**

![General synthetic route I diagram]

**Synthetic routes to nitrile intermediates:**

![Synthetic routes to nitrile intermediates diagram]

**Intermediate-1**

4-(4-Fluoro-phenyl)-4-oxo-butyric acid – Representative Procedure 1a (RP1a):
Succinic anhydride (1.0 g, 10 mmol) was dissolved in 4-fluorobenzene (3.75 ml, 40
mmol) and cooled to -9 °C under nitrogen. AlCl₃ (2.67 g; 20 mmol) was added, and the temperature was kept between -9 and 0 °C for 4½ hours. The reaction was allowed to warm to room temperature and stirred over night. The reaction mixture was poured into aqueous 4 M HCl (10 ml) at 0 °C, and the precipitated was filtered and washed with water. The solid was recrystallized from toluene to give 1.40 g (71 %) of a colorless solid: LC/MS (an10n8): Rt 0.26 min, m/z 195 [M – H], 413 [2M-2H+Na]; ¹H NMR (CDCl₃): δ 2.84 (t, J = 6.5 Hz, 2H), 3.31 (t, J = 6.5 Hz, 2H), 7.16 (m, 3H), 8.03 (m, 2H).

In an analogous way, the following compounds were made:

**Intermediate-2**

**4-(2,5-Dimethoxy-phenyl)-4-oxo-butyric acid.** LC/MS (an10n8): Rt 0.50 min, m/z 237 [M-H], 497 [2M-2H+Na]; ¹H NMR (DMSO-d₆): δ 2.53 (t, J = 6.0 Hz, 2H), 3.16 (t, J = 6.3 Hz, 2H), 3.73 (s, 3H), 3.85 (s, 3H), 7.12-7.14 (m, 3H). ¹³C NMR/APT (DMSO-d₆): δ 29.1 (CH2), 39.2 (CH2), 56.4 (CH3), 57.2 (CH3), 114.5 (CH), 115.0 (CH), 120.4 (CH), 128.5 (C), 153.8 (C), 174.7 (CO), 200.2 (CO).

**Intermediate-3**

**4-Oxo-4-(4-phenoxy-phenyl)-butyric acid.** ¹H NMR (DMSO-d₆): δ 2.57 (t, J = 6.22, 2H), 3.21 (t, J = 6.22, 2H), 7.05 (m, 2H), 7.13 (m, 2H), 7.25 (m, 1H), 7.47 (m, 2H), 8.01 (m, 2H), 12.13 (br s, 1H (COOH)).

**Intermediate-4**

**4-(5-Chloro-2-methoxy-phenyl)-4-oxo-butyric acid.** ¹H NMR (DMSO-d₆): δ 2.53 (t, J = 6.6 Hz, 2H), 3.15 (t, J = 6.0 Hz, 2H), 3.90 (s, 3H), 7.23 (d, J = 8.9 Hz, 1H), 7.53 (d, J = 2.6 Hz, 1H), 7.60 (dd, J = 2.9, 8.9 Hz, 1H) and 12.11 (br s, 1H).

**Intermediate-5**
4-(3-Fluoro-phenyl)-4-oxo-butyric acid – Representative Procedure 1b (RP1b): In a flame dried flask under nitrogen, succinic anhydride (471 mg, 4.7 mmol) was dissolved in dry THF (5 mL). The mixture was cooled to -78 °C. 3-Fluorophenyl-magnesium bromide in THF (1N, 5 mL, 5 mmol) was added slowly. The mixture was stirred at -78 °C for 3 h, then allowed to raise room temperature. The mixture was transferred into 1N HCl (aq.) then extracted with CH₂Cl₂. The organic layer was dried and evaporated. The residue was purified by flash chromatography on SiO₂ to give 350 mg (38%) of the title compound: ¹H NMR (CDCl₃): δ 2.84 (t, J = 6.5 Hz, 2H), 3.31 (t, J = 6.5 Hz, 2H), 7.30 (m, 1H), 7.47 (td, J = 8.1, 5.7, 1H), 7.68 (m, 1H), 7.79 (m, 1H).

The following compounds were prepared by an analogous procedure:

**Intermediate-6**

4-(3,4-Difluoro-phenyl)-4-oxo-butyric acid. ¹H NMR (CDCl₃): δ 2.57 (t, J = 6.2 Hz, 2H), 3.25 (t, J = 6.2 Hz, 2H), 7.60 (m, 1H), 7.87 (m, 1H), 8.02 (m, 1H), 12.17 (br s, 1H).

**Intermediate-7**

4-Oxo-4-(4-trifluoromethyl-phenyl)-butyric acid. 4-Iodobenzotrifluoride (500 µL, 3.4 mmol) was dissolved in dry diethylether (5 mL) in a flamedried flask under nitrogen. Magnesium (83 mg, 3.4 mmol) was added and the mixture was stirred at room temperature for 45 min. Succinic anhydride was dissolved in THF (5 mL) in a flamedried flask under nitrogen then cooled to -78°C. The freshly made Grignard reagent was added slowly. The mixture was allowed to warm to room temperature over 3 h. The mixture was transferred into NH₄Cl (aq.) then extracted with CH₂Cl₂. The organic layer was dried (MgSO₄) then evaporated. The product was purified by flash chromatography on SiO₂ to give 250 mg (30%): ¹H NMR (CDCl₃): δ 2.86 (t, J = 6.4 Hz, 2H), 3.35 (t, J = 6.4 Hz, 2H), 7.76 (d, J = 8.3 Hz, 2H), 8.10 (d, J = 8.3 Hz, 2H).

**Intermediate-8**
3-Bromo-4-(4-fluoro-phenyl)-4-oxo-butyric acid – Representative Procedure 2 (PR2): 4-(4-Fluoro-phenyl)-4-oxo-butyric acid (1.20 g, 6.12 mmol) was suspended in ether (10 mL) at room temperature. Bromine (0.34 ml, 6.73 mmol) was added dropwise. After 4 hours, the reaction was concentrated and the residue was recrystallized from ether/heptane to give 1.26 g (75%) of pale orange crystals. $^1$H NMR (CDCl$_3$): $\delta$ 3.16 (dd, $J = 2.2, 6.9$ Hz, 1H), 3.56 (dd, $J = 3.5, 6.9$ Hz, 1H), 5.41 (dd, $J = 2.2, 3.5$ Hz, 1H), 7.19 (m, 2H), 8.08 (m, 2H); $^{13}$C NMR/APT (CDCl$_3$): $\delta$ 190.9, 175.6, 168.3, 164.9, 132.3, 132.1, 116.6, 116.3, 38.8, 38.3.

In an analogous way, the following compounds were made:

**Intermediate-9**

3-Bromo-4-(4-chloro-phenyl)-4-oxo-butyric acid. $^1$H NMR (CDCl$_3$, 300 MHz): $\delta$ 3.18 (dd, $J = 5.7, 17.5$ Hz, 1H), 3.52 (dd, $J = 8.5, 17.5$ Hz, 1H), 5.43 (dd, $J = 5.8, 8.5$ Hz, 1H), 6.99 (d, $J = 8.9$ Hz, 2H), 8.10 (d, $J = 8.9$ Hz, 2H).

**Intermediate-10**

3-Bromo-4-oxo-4-phenyl-butyric acid. LC/MS (an10p8): Rt 2.69 min, $m/z$ 257/259 [M+H], 279/281 [M+Na]; $^1$H NMR (CDCl$_3$): $\delta$ 3.17 (dd, $J = 5.7, 17.6$ Hz, 1H), 3.56 (dd, $J = 8.7, 17.6$ Hz, 1H), 5.46 (dd, $J = 5.7, 8.7$ Hz, 1H), 7.52 (m, 2H), 7.64 (m, 1H), 8.05 (m, 2H).

**Intermediate-11**

3-Bromo-4-(4-methoxy-phenyl)-4-oxo-butyric acid. $^1$H NMR (CDCl$_3$): $\delta$ 3.17 (dd, $J = 5.7, 17.7$ Hz, 1H), 3.55 (dd, $J = 9.0, 17.7$ Hz, 1H), 3.91 (s, 3H), 5.40 (dd, $J = 5.5, 8.9$ Hz, 1H), 7.51 (d, $J = 8.7$ Hz, 2H), 7.98 (d, $J = 8.7$ Hz, 2H).

**Intermediate-12**
3-Bromo-4-(3-fluoro-phenyl)-4-oxo-butyric acid. $^1$H NMR (CDCl$_3$): δ 3.18 (m, 1H), 3.54 (m, 1H), 5.39 (m, 1H), 7.34 (m, 1H), 7.50 (m, 1H), 7.83 (m, 2H) and 10.11 (br s, 1H).

Intermediate-13

3-Bromo-4-(3,4-difluoro-phenyl)-4-oxo-butyric acid. $^1$H NMR (CDCl$_3$): δ 3.16 (dd, $J = 17.7$, 5.3 Hz, 1H), 3.55 (dd, $J = 17.7$, 9.0 Hz, 1H), 5.32 (dd, $J = 9.0$, 5.5 Hz, 1H), 7.31 (m, 1H), 7.85 (m, 2H).

Intermediate-14

3-Bromo-4-oxo-4-(4-trifluoromethyl-phenyl)-butyric acid. $^1$H NMR (CDCl$_3$): δ 3.19 (dd, $J = 17.7$, 5.5 Hz, 1H), 3.59 (dd, $J = 17.5$, 9.0 Hz, 1H), 5.44 (dd, $J = 9.0$, 5.5 Hz, 1H), 7.79 (d, $J = 2.8$ Hz) and 8.16 (d, $J = 3.0$ Hz).

Intermediate-15

3-(4-Chloro-phenyl)-2-phenyl-propionitrile – Representative Procedure 3 (RP3):
The reaction was preformed under N$_2$ in flame dried glassware. Benzylcyanide (1.2 mL, 10 mmol) was added slowly (over a period of 40 min) to a solution of LDA (10 mmol) in THF (10 mL) at -78°C. The mixture was stirred for 1 h at -78°C, and then added slowly (over a period of 16 min) to a solution of 4-chlorobenzyl bromide in THF (10 mL) at -78°C. The mixture was stirred for 1 h at -78°C and left over night to reach room temperature. The reaction mixture was added saturated aq. NH$_4$Cl and the aqueous mixture was extracted with EtOAc. The organic phase was washed with brine, dried (MgSO$_4$) and concentrated, and the residue was recrystallized from heptane to give 1.26 g (53%) of a light brown powder. $^1$H NMR (CDCl$_3$): δ 3.16 (m, 2H) and 4.01 (t, $J = 7.2$ Hz, 1H), 7.05 (d, $J = 8.3$ Hz, 2H), 7.32 (m, 7H).

In an analogous way, the following compounds were made:
Intermediate-16

2,3-Diphenyl-propionitrile. $^1$H NMR (CDCl$_3$): $\delta$ 3.19 (m, 2H) and 4.02 (t, $J = 7.9$ Hz, 1H).

Intermediate-17

2-(4-Chloro-phenyl)-3-phenyl-propionitrile. $^1$H NMR (CDCl$_3$): $\delta$ 3.16 (m, 2H) and 4.14 (t, $J = 7.2$ Hz, 1H).

Intermediate-18

(4-Chloro-phenyl)-phenyl-acetonitrile – Representative Procedure 4 (RP4): The reaction was preformed under N$_2$ and flame-dried glassware. 4-Chlorobenzyl cyanide (1 mL; 7.8 mmol) was dissolved in benzene (10 mL) and heated to reflux. Bromide (442 $\mu$L; 8.6 mmol) was added over 30 min. The mixture was stirred 20 min at reflux, then cooled to approx 40°C and added over 30 min to a refluxing mixture of aluminum chloride (1 g; 7.8 mmol) in benzene (10 mL). The mixture was stirred 1 h at reflux then cooled to r.t. The mixture was transferred into ice and conc. HCl (50 mL) then extracted with diethyl ether. The organic layer was dried (MgSO$_4$) and concentrated in vacuum to give brown oil. The product was purified by flash chromatography on SiO$_2$ to give 523 mg (28%) yellow oil. $^1$H NMR (CDCl$_3$): $\delta$ 5.14 (s, 1H) and 7.36 (m, 9H). APT (CDCl$_3$): $\delta$ 42.42 (CH).

In an analogous way, the following compounds were made:

Intermediate-19

(4-Fluoro-phenyl)-phenyl-acetonitrile. $^1$H NMR (CDCl$_3$): $\delta$ 5.15 (s, 1H), 7.08 (m, 2H), 7.36 (m, 7H).
Intermediate-20

(3,4-Difluoro-phenyl)-phenyl-acetonitrile. $^1$H NMR (CDCl$_3$, 300 MHz): δ 5.12 (s, 1H), 7.15 (m, 3H), 7.41 (m, 5H).

Intermediate-21

Bis-(4-fluoro-phenyl)-acetonitrile. 4,4'-Difluorobenzhydrol (1 g, 4.54 mmol) was dissolved in TFA (10 mL). Potassium cyanide (620 mg, 9.53 mmol) was added and the mixture was cooled to 0°C. Sulfuric acid (conc., 3 mL) was added slowly. The mixture was stirred at room temperature for 5h then quenched with H$_2$O and ethyl acetate. The organic phase was washed with water and brine, dried (MgSO$_4$) and concentrated. The residue was purified by flash chromatography on SiO$_2$ to give 450 mg (43%) of the title compound: $^1$H NMR (CDCl$_3$): δ 5.14 (s, 1H), 7.09 (m, 4H) and 7.32 (m, 4H). $^{13}$C NMR (APT, CDCl$_3$): δ 41.53 (CH).

Intermediate-22

Bis-(4-methoxy-phenyl)-acetonitrile. 4,4'-Dimethoxybenzhydrol (5 g, 20 mmol) was dissolved in dry CH$_2$Cl$_2$ (50 mL) then cooled to 0 °C. Thionyl chloride (1.5 mL, 20 mmol) was added slowly. The mixture was stirred at room temperature for 4h. The mixture was concentrated under vacuum. The product was dissolved in dry CH$_2$Cl$_2$ (10 mL) and added to a mixture of potassium cyanide (2.6 g, 40 mmol) and 18-crown-6 (500 mg) dissolved in dry CH$_2$Cl$_2$ (20 mL). The mixture was stirred over night at room temperature. The mixture was transferred into water then extracted with CH$_2$Cl$_2$. The organic layer was washed with water and brine, dried (MgSO$_4$) and concentrated. The residue was recrystallized from ethyl acetate to give 2.54 g (50%) of the title compound: $^1$H NMR (CDCl$_3$): δ 3.82 (s, 6H), 5.07 (s, 1H), 6.90 (m, 4H), 7.25 (m, 4H).

Intermediate-23
(4-Methoxy-phenyl)-phenyl-acetonitrile. (4-Methoxyphenyl)acetonitrile (5 mL, 37 mmol) was dissolved in dry benzene (10 mL) in a flamedried flask under nitrogen. The mixture was heated to reflux and bromine (1.9 mL, 37 mmol) was added in small portions over 2 h. The mixture was stirred at reflux for 30 min, then added to a refluxing mixture of AlCl₃ (4.9 g, 37 mmol) in benzene (30 mL) over 80 min. The mixture was stirred at reflux for 1 h then cooled to room temperature. The mixture was transferred into 1N HCl and ice then extracted with diethylether. The organic layer was dried (MgSO₄) and concentrated. The product was purified by flash chromatography on SiO₂ to give 1.3 g (16%) of the title compound: ¹H NMR (CDCl₃): δ 3.82 (s, 3H), 5.12 (s, 1H), 6.90 (m, 2H), 7.27 (m, 2H), 7.37 (m, 5H).

Intermediate-24

2-(4-Chloro-phenyl)-3-phenyl-thiopropionamide – Representative Procedure 5 (RP5): 2-(4-Chloro-phenyl)-3-phenyl-propionitrile (200 mg, 0.8 mmol) was dissolved in pyridine (5 mL) and triethylamine (1 mL). The mixture was saturated with hydrogen sulfide and stirred under an atmosphere of hydrogen sulfide room temperature for 3 days. The mixture was extracted with EtOAc. The extract was washed with brine, dried (MgSO₄) and concentrated to give 250 mg of crude product, which was used directly in the next step. ¹H NMR (DMSO-d6): δ 3.17 (dd, J = 8.1, 13.8 Hz, 1H), 3.75 (dd, J = 7.0, 13.8 Hz, 1H), 4.03 (t, J = 7.5 Hz, 1H) and 7.20 (m, 9H).

In an analogous way, the following compounds were made:

Intermediate-25

2-Phenyl-thiobutyramide. LC/MS (an10p8): Rt 2.9 min, m/z 180 [M + 1]. ¹H NMR (CDCl₃): δ 0.93 (t, 3H); 2.01 (m, 1H); 2.41 (m, 1H); 3.75 (dd, 1H); 6.75 (br s, 1H); 7.36 (m, 5H); 7.58 (br s, 1H).

Intermediate-26
2-(4-Chloro-phenyl)-2-phenyl-thioacetamide. $^1$H NMR (CDCl$_3$): $\delta$ 5.59 (s, 1H).

Intermediate-27

3-(4-Chloro-phenyl)-2-phenyl-thiopropionamide. $^1$H NMR (DMSO-d$_6$): $\delta$ 3.14 (m, 1H), 3.77 (dd, $J$ = 6.6, 13.9 Hz, 1H), 4.00 (t, $J$ = 7.73 Hz, 1H).

Intermediate-28

2,2-Bis-(4-fluoro-phenyl)-thioacetamide. $^1$H NMR (CDCl$_3$): $\delta$ 5.57 (s, 1H), 6.76 (br s, 1H (NH)), 7.08 (m, 4H) and 7.23 (m, 4H) and 7.68 (br s, 1H (NH)).

Intermediate-29

2,2-Bis-(4-methoxy-phenyl)-thioacetamide. LC/MS (an10p8): Rt 2.96 min, m/z 288 [M + H]. $^1$H NMR (CDCl$_3$): $\delta$ 3.81 (s, 6H), 5.54 (s, 1H), 6.83 (bs, 1H (NH)), 6.90 (m, 4H), 7.18 (m, 4H), 7.73 (br s, 1H (NH)).

Intermediate-30

2-(4-Methoxy-phenyl)-2-phenyl-thioacetamide. $^1$H NMR (CDCl$_3$): $\delta$ 3.82 (s, 3H), 5.59 (s, 1H), 6.83 (bs, 1H (NH)), 6.90 (m, 2H), 7.18 (m, 2H), 7.35 (m, 5H), 7.76 (bs, 1H (NH)).

Intermediate-31

2-(4-Fluoro-phenyl)-2-phenyl-thioacetamide. $^1$H NMR (CDCl$_3$): $\delta$ 5.61 (s, 1H), 6.84 (br s, 1H (NH)), 7.06 (m, 2H), 7.26 (m, 2H), 7.37 (m, 5H), 7.86 (br s, 1H (NH)).

Intermediate-32

27
2-(3,4-Difluoro-phenyl)-2-phenyl-thioacetamide. $^1$H NMR (CDCl$_3$): $\delta$ 5.56 (s, 1H), 6.81 (br s, 1H (NH)), 7.04 (m, 1H), 7.14 (m, 2H), 7.25 (m, 2H), 7.38 (m, 3H), 7.92 (br s, 1H (NH)).

A1

[2-Benzhydryl-4-(4-chloro-phenyl)-thiazol-5-yl]-acetic acid – Representative Procedure 6 (RP6): 3-Bromo-4-(4-chlorophenyl)-4-oxo-butyric acid (119 mg, 0.4 mmol) and 2,2-diphenyl-thioacetamide (91 mg, 0.4 mmol) was dissolved in DMF (1 mL) and heated to 100 °C for 10 minutes in a microwave oven. The reaction mixture was poured into water at 0 °C. The precipitation was filtered off and recrystallized from CH$_2$Cl$_2$ to give 77 mg (54%) yellow powder: $^1$H NMR (DMSO-d$_6$): $\delta$ 3.91 (s, 2H), 5.96 (s, 1H), 7.37 (m, 10H), 7.52 (d, $J = 8.48$ Hz, 2H), 7.60 (d, $J = 8.67$ Hz, 2H), 12.82 (br s, 1H (COOH)).

In an analogous way, the following compounds were made:

A2

[2-Benzhydryl-4-(2,5-dimethoxy-phenyl)-thiazol-5-yl]-acetic acid. LC/MS (an10p8): Rt 3.18 min, m/z 446 [M + 1]; $^1$H NMR (DMSO-d$_6$): $\delta$ 3.59 (s, 2H), 5.92 (s, 1H), 6.85 (d, $J = 3.0$ Hz, 1H), 6.96 (dd, $J = 8.9$ and 3.0 Hz), 7.04 (d, $J = 8.5$ Hz), 7.22-7.45 (m, 10H).

A3

[2-Benzhydryl-4-(5-chloro-2-methoxy-phenyl)-thiazol-5-yl]-acetic acid. LC/MS (an10p8): Rt 3.70 min, m/z 450 [M + 1]; $^1$H NMR (DMSO-d$_6$): $\delta$ 3.60 (s, 2H), 3.73 (s, 3H), 5.93 (s, 1H), 7.14 (d, $J = Hz$, 1H), 7.28 (m, 3H), 7.36 (m, 8H), 7.44 (m, 1H).
[2-Benzhydryl-4-(4-fluoro-phenyl)-thiazol-5-yl]-acetic acid. LC/MS (an10p8): Rt 2.93 min, m/z 404 [M + 1]; \(^1\)H NMR (CDCl\(_3\)): \(\delta\) 3.85 (s, 2H), 5.88 (s, 1H), 7.12 (m, 2H), 7.25-7.38 (m, 10H), 7.58 (m, 2H).

[4-(4-Chloro-phenyl)-2-(1,2-diphenyl-ethyl)-thiazol-5-yl]-acetic acid. LC/MS (an10p8): Rt 4.74 min, m/z 434 [M + 1]; \(^1\)H NMR (DMSO-d\(_6\)): \(\delta\) 3.32 (m, 1H), 3.61 (m, 1H), 3.85 (s, 2H (CH\(_2\))), 4.75 (m, 1H (CH)).

[4-(4-Chloro-phenyl)-2-(1-phenyl-propyl)-thiazol-5-yl]-acetic acid: LC/MS (an10p8): Rt 3.1 min, m/z 372 [M+1].

[2-[1-(4-Chloro-phenyl)-2-phenyl-ethyl]-4-(4-fluoro-phenyl)-thiazol-5-yl]-acetic acid. \(^1\)H NMR (DMSO-d\(_6\)): \(\delta\) 3.32 (m, 1H), 3.61 (m, 1H), 3.84 (s, 2H (CH\(_2\))), 4.80 (m, 1H (CH)).
{4-(4-Chloro-phenyl)-2-[(4-chloro-phenyl)-phenyl-methyl]-thiazol-5-yl]-acetic acid. $^1$H NMR (DMSO-d$_6$): $\delta$ 3.91 (s, 2H), 6.01 (s, 1H), 7.37 (m, 9H), 7.50 (d, $J = 8.10$ Hz, 2H), 7.60 (d, $J = 8.29$ Hz, 2H).

A9

{4-(4-Chloro-phenyl)-2-[1-(4-chloro-phenyl)-2-phenyl-ethyl]-thiazol-5-yl]-acetic acid. LC/MS (an10p8): Rt 5.17 min, m/z 469 [M+1]; $^1$H NMR (DMSO-d$_6$): $\delta$ 3.32 (m, 1H), 3.61 (dd, $J = 6.90$ and 13.94, 1H), 3.86 (s, 2H (CH$_2$)) and 4.81 (t, $J = 7.90$, 1H (CH)).

A10

[2-[(4-Chloro-phenyl)-phenyl-methyl]-4-(4-fluoro-phenyl)-thiazol-5-yl]-acetic acid. LC/MS (an10p8): Rt 5.04 min, m/z 438 [M + 1]; $^1$H NMR (DMSO-d$_6$): $\delta$ 3.83 (s, 2H), 5.86 (s, 1H), 7.11 (m, 2H), 7.20-7.40 (m, 9H), 7.55 (m, 2H).

A11

(2-Benzhydryl-4-phenyl-thiazol-5-yl)-acetic acid. LC/MS (an10p8): Rt 3.95 min, m/z 386 [M + H]; $^1$H NMR (CDCl$_3$): $\delta$ 3.85 (s, 2H), 6.01 (s, 1H), 7.22-7.48 (m, 12H) and 7.60 (m, 2H).

A12

[2-Benzhydryl-4-(4-methoxy-phenyl)-thiazol-5-yl]-acetic acid. LC/MS (an10p8): Rt 3.52 min, m/z 416 [M + H]; $^1$H NMR (CDCl$_3$): $\delta$ 3.84 (s, 3H), 3.85 (s, 2H), 5.86 (s, 1H), 6.97 (m, 2H), 7.26-7.37 (m, 10H) and 7.54 (m, 2H).
A13

{4-(4-Chloro-phenyl)-2-[(4-fluoro-phenyl)-phenyl-methyl]-thiazol-5-yl]-acetic acid. LC/MS (an10p8): Rt 0.98 min, m/z 438 [M + H]; $^1$H NMR (DMSO-d$_6$): δ 3.91 (s, 2H), 6.00 (s, 1H), 7.19 (m, 2H), 7.29 (m, 1H), 7.36-7.43 (m, 6H), 7.54 (m, 2H), 7.59 (m, 2H), 12.87 (br s, 1H).

A14

[2-[(Bis-(4-fluoro-phenyl)-methyl]-4-(4-fluoro-phenyl)-thiazol-5-yl]-acetic acid.

LC/MS (an10p8): Rt 4.81 min, m/z 440 [M + H]; $^1$H NMR (DMSO-d$_6$): δ 3.89 (s, 2H), 6.03 (s, 1H), 7.19 (m, 4H), 7.30 (m, 2H), 7.41 (m, 4H), 7.62 (m, 2H).

A15

{4-(4-Fluoro-phenyl)-2-[(4-methoxy-phenyl)-phenyl-methyl]-thiazol-5-yl]-acetic acid. LC/MS (an10p8): Rt 3.45 min, m/z 434 [M + H]; $^1$H NMR (CDCl$_3$): δ 3.81 (s, 3H), 3.84 (s, 2H), 5.81 (s, 1H), 6.89 (m, 2H), 7.12 (m, 2H), 7.24 (m, 2H), 7.28-7.38 (m, 5H), 7.58 (m, 2H). $^{13}$C-APT (CDCl$_3$): δ 32.79 (CH$_2$), 54.62, 55.65 (CH$_3$/CH).

A16

{4-(4-Chloro-phenyl)-2-[(4-methoxy-phenyl)-phenyl-methyl]-thiazol-5-yl]-acetic acid. LC/MS (an10p8): Rt 3.71 min, m/z 450 [M + H]; $^1$H NMR (CDCl$_3$): δ 3.81 (s, 3H), 3.84 (s, 2H), 5.84 (s, 1H), 6.87 (m, 2H), 7.21 (m, 2H), 7.24-7.36 (m, 5H), 7.41 (m, 2H), 7.55 (m, 2H). $^{13}$C-APT (CDCl$_3$): δ 32.83 (CH$_2$), 54.57, 55.66 (CH$_3$ / CH).
A17

{4-(4-Chloro-phenyl)-2-[[3,4-difluoro-phenyl]-phenyl-methyl]-thiazol-5-yl]-acetic acid. LC/MS (an10p8): Rt 3.98 min, m/z 456 [M + H]; \(^1^H\) NMR (CDCl\(_3\)): 6 3.89 (s, 2H), 5.79 (s, 1H), 7.04 (m, 1H), 7.15 (m, 2H), 7.25-7.40 (m, 5H), 7.44 (m, 2H), 7.53 (m, 2H). \(^{13}\)C-APT (CDCl\(_3\)): 6 32.60 (CH\(_2\)), 54.54 (CH).

A18

[2-[[3,4-Difluoro-phenyl]-phenyl-methyl]-4-(4-fluoro-phenyl)-thiazol-5-yl]-acetic acid. LC/MS (an10p8): Rt 3.76 min, m/z 440 [M + H]; \(^1^H\) NMR (CDCl\(_3\)): 6 3.88 (s, 2H), 5.83 (s, 1H), 7.03 (m, 1H), 7.14 (m, 4H), 7.28-7.44 (m, 5H), 7.58 (m, 2H). \(^{13}\)C-APT (CDCl\(_3\)): 6 32.65 (CH\(_2\)), 54.46 (CH).

A19

{4-(4-Fluoro-phenyl)-2-[phenyl-(4-trifluoromethyl-benzoylamino)-methyl]-thiazol-5-yl]-acetic acid. LC/MS (an10p8): Rt 2.88 min, m/z 515 [M + H]; \(^1^H\) NMR (DMSO-d\(_6\)): 6 3.90 (s, 2H), 6.64 (d, J = 8.2 Hz, 1H), 7.30 (m, 2H), 7.36-7.45 (m, 3H), 7.54-7.65 (m, 4H), 7.87 (d, J = 8.2 Hz, 2H), 8.16 (d, J = 8.2 Hz, 2H), 9.87 (m, 1H (NH)) and 12.82 (s, 1H (OH)).

A20

[2-[Bis-(4-methoxy-phenyl)-methyl]-4-(4-fluoro-phenyl)-thiazol-5-yl]-acetic acid. LC/MS (an10p8): Rt 2.17 min, m/z 464 [M + H]; \(^1^H\) NMR (CDCl\(_3\)): 6 3.81 (s, 6H), 3.83 (s, 2H), 5.77 (s, 1H), 6.89 (m, 4H), 7.11 (m, 2H), 7.22 (m, 4H), 7.56 (m, 2H).
A21
[2-Benzhydryl-4-(4-phenoxy-phenyl)-thiazol-5-yi]-acetic acid. LC/MS (an10p8): Rt 4.04 min, m/z 478 [M + H]; $^1$H NMR (CDCl$_3$): $\delta$ 3.88 (s, 2H), 5.87 (s, 1H), 7.07 (m, 4H), 7.14 (m, 1H), 7.25-7.41 (m, 12H), 7.58 (m, 2H).

A22
{4-(4-Fluoro-phenyl)-2-[(4-hydroxy-phenyl)-phenyl-methyl]-thiazol-5-yi]-acetic acid. $^1$H NMR (CDCl$_3$): $\delta$ 3.77 (s, 2H), 5.82 (s, 1H), 6.70 (m, 2H), 7.02-7.15 (m, 5H), 7.26-7.30 (m, 4H), 7.53 (m, 2H).

A23
[2-Benzhydryl-4-(3-fluoro-phenyl)-thiazol-5-yi]-acetic acid. LC/MS (an10p8): Rt 2.69 min, m/z 404 [M + H]; $^1$H NMR (CDCl$_3$): $\delta$ 3.88 (s, 2H), 5.90 (s, 1H), 7.07 (m, 1H), 7.26-7.41 (m, 13H).

A24
[2-Benzhydryl-4-(3-fluoromethyl-phenyl)-thiazol-5-yi]-acetic acid. LC/MS (an10p8): Rt 3.09 min, m/z 455 [M + H]; $^1$H NMR (CDCl$_3$): $\delta$ 3.91 (s, 2H), 5.91 (s, 1H), 7.34 (m, 10H), 7.72 (m, 4H).

A25
[2-[Bis-(4-fluoro-phenyl)-methyl]-4-(3,4-difluoro-phenyl)-thiazol-5-yl]-acetic acid. LC/MS (an10p8): Rt 3.18 min, m/z 458 [M + H]; ¹H NMR (CDCl₃): δ 3.88 (s, 2H), 5.81 (s, 1H), 7.04 (m, 4H), 7.18-7.36 (m, 6H), 7.46 (m, 1H).

A26

[2-Benzhydryl-4-(3,4-difluoro-phenyl)-thiazol-5-yl]-acetic acid. LC/MS (an10p8): Rt 2.88 min, m/z 422 [M + H]; ¹H NMR (CDCl₃): δ 3.88 (s, 2H), 5.81 (s, 1H), 7.20 (m, 1H), 7.26-7.37 (m, 9H), 7.48 (m, 1H).

A27

[2-[Bis-(4-fluoro-phenyl)-methyl]-4-(3-fluoro-phenyl)-thiazol-5-yl]-acetic acid. LC/MS (an10p8): Rt 3.08 min, m/z 440 [M + H]; ¹H NMR (CDCl₃): δ 3.92 (s, 2H), 5.82 (s, 1H), 7.04 (m, 4H), 7.24-7.29 (m, 6H) and 7.37 (m, 2H).

Synthesis of nitrile intermediates – Representative Procedure 7 (RP7): To a cooled (5 °C) solution of Potassium tert-butoxide (2.1 mmol) in dry DMF (0.6ml) was added a mixture of the benzonitrile (1 mmol) and the 2-Chloro-pyridine (1.1 mmol) in dry DMF (0.4ml). After O/N stirring at RT, aq. NH₄Cl and EtOAc were added. The organic phase was separated, dried over MgSO₄ and concentrated in vacuo. The residue was purified over silica gel chromatography to give the desired product, which precipitated upon treatment with Et₂O.
[4-(4-Chloro-phenyl)-2-(phenyl-pyridin-2-yl-methyl)-thiazol-5-yl]-acetic acid.
Title compound was prepared from 3-bromo-4-(4-chloro-phenyl)-4-oxo-butyric acid and 2-phenyl-2-pyridin-2-yl-thioacetamide according to RP6 and RP7: LC/MS (an10p8) Rt 3.00 min, m/z 422 [M + H]⁺; ¹H NMR (CDCl₃): δ 3.86 (s, 2H), 6.2 (s, 1H), 7.2-8.0 (m, 12H), 8.7 (d, 1H).

A29

{4-(4-Chloro-phenyl)-2-[3-chloro-pyridin-2-yl]-phenyl-methyl]-thiazol-5-yl}-acetic acid. Title compound was prepared from 3-bromo-4-(4-chloro-phenyl)-4-oxo-butyric acid and 2-(3-Chloro-pyridin-2-yl)-2-phenyl-thioacetamide according to RP6 and RP7: LC/MS (an10p8) Rt 3.54 min, m/z 454.5 [M + H]⁺; ¹H NMR (CDCl₃): δ 3.83 (s, 2H), 6.66 (s, 1H), 7.2-7.3 (m, 1H), 7.3-7.4 (m, 5H), 7.5 (d, 4H), 7.7 (dd, 1H), 8.6 (dd, 1H).

A30

{4-(4-Fluoro-phenyl)-2-[(4-methoxy-phenyl)-pyridin-2-yl-methyl]-thiazol-5-yl}-acetic acid. Title compound was prepared from 3-bromo-4-(4-fluoro-phenyl)-4-oxo-butyric acid and 2-(4-methoxy-phenyl)-2-pyridin-2-yl-thioacetamide according to RP6 and RP7: LC/MS (an10p8) Rt 2.20 min, m/z 434 [M + H]⁺.

A31

{4-(4-Chloro-phenyl)-2-[(4-methoxy-phenyl)-pyridin-2-yl-methyl]-thiazol-5-yl}-acetic acid. Title compound was prepared from 3-bromo-4-(4-chloro-phenyl)-4-oxo-butyric acid and 2-(4-methoxy-phenyl)-2-pyridin-2-yl-thioacetamide according to RP6 and RP7: LC/MS (an10p8) Rt 2.37 min, m/z 450.5 [M + H]⁺; ¹H NMR (CDCl₃): δ 3.75 (s, 3H), 3.78 (s, 2H) 6.0 (s, 1H), 6.9 (d, 2H), 7.2 (t, 1H), 7.3 (m, 4H), 7.4 (d, 1H), 7.5 (d, 2H), 7.6 (dt, 1H), 8.1 (d, 1H).
A32

[4-(4-Chloro-phenyl)-2-(cyclohexyl-phenyl-methyl)-thiazol-5-yl]-acetic acid. Title compound was prepared from 3-bromo-4-(4-chloro-phenyl)-4-oxo-butryic acid and 2-cyclohexyl-2-phenyl-thioacetamide according to RP6: LC/MS (an10p8) Rt 3.20 min, m/z 425.4 [M + H]+.

A33

[2-[(Cyclobutanecarbonyl-amino)-phenyl-methyl]-4-(4-fluoro-phenyl)-thiazol-5-yl]-acetic acid. Title compound was prepared from 3-bromo-4-(4-fluoro-phenyl)-4-oxo-butryic acid and 2-cyclobutyl-2-phenyl-thioacetamide according to RP6: LC/MS (an10p8): Rt 2.01 min, m/z 425 [M + H]; 1H NMR (CDCl3): δ 1.92 (m, 2H), 2.19 (m, 2H), 3.13 (p, J = 8.4 Hz, 1H), 3.81 (s, 2H), 6.49 (d, J = 7.5, 1H (NH)), 7.13 (m, 3H), 7.36 (m, 4H) and 7.54 (m, 2H).

A34

[2-Biphenyl-2-ylmethyl-4-(4-chloro-phenyl)-thiazol-5-yl]-acetic acid. Title compound was prepared from 3-bromo-4-(4-chloro-phenyl)-4-oxo-butryic acid and 2-biphenyl-2-yl-thioacetamide according to RP6: LC/MS (an10p8) Rt 4.94 min, m/z 419.4 [M + H]+; 1H NMR (CDCl3): δ 3.83 (s, 2H), 4.33 (s, 2H), 7.3-7.5 (m, 13H).

A35

[4-(4-Chloro-phenyl)-2-(2-phenoxy-benzyl)-thiazol-5-yl]-acetic acid. Title compound was prepared from 3-bromo-4-(4-chloro-phenyl)-4-oxo-butryic acid and 2-(2-phenoxy-phenyl)-thioacetamide according to RP6: LC/MS (an10p8) Rt 3.80 min, m/z 435.4 [M + H]+; 1H NMR (CDCl3): δ 3.82 (s, 2H), 4.39 (s, 2H), 6.9 (d, 1H), 7.0 (d, 2H), 7.1 (m, 2H), 7.2-7.3 (m, 3H), 7.4 (t, 3H), 7.5 (d, 2H).
**[2-Biphenyl-2-ylmethyl-4-(4-fluoro-phenyl)-thiazol-5-yl]-acetic acid.** Title compound was prepared from 3-bromo-4-(4-fluoro-phenyl)-4-oxo-butyric acid and 2-biphenyl-2-yl-thioacetamide according to RP6: LC/MS (an10p8) Rt 2.60 min, m/z 403 [M + H]⁺; ¹H NMR (CDCl₃): δ 3.78 (s, 2H), 4.31 (s, 2H), 7.1 (t, 2H), 7.3-7.5 (m, 11H).

**Representative procedure 8 (RP8)**
A mixture of Pd(PPh₃)₄ (~50mg), K₂CO₃ (2 mmol), [2-(2-bromo-benzyl)- thiazol-5-yl]-acetic acid (1 mmol) and the corresponding phenyl boronic acid (1.3 mmol) in DME/H₂O/EtOH (7/3/2, 20 mL) was heated at 150 °C for 10 minutes in a microwave. After cooling, water, acetic acid and EtOAc were added. The solid materials were filtered off and the filtrate was concentrated in vacuo. The residue was taken up in hot acetonitrile and solid particles were filtered off. The filtrate was allowed to cool to RT, upon which the desired compound precipitated. In some occasions, the crude material was purified by chromatography.

**Intermediate-33**
[2-(2-Bromo-benzyl)-4-(4-fluoro-phenyl)-thiazol-5-yl]-acetic acid. Title compound was prepared from 3-bromo-4-(4-fluoro-phenyl)-4-oxo-butyric acid and 2-(2-bromo-phenyl)-thioacetamide according to RP6: LC/MS (an10p8) Rt 2.22 min, m/z 405.4 [M + H]⁺; ¹H NMR (CDCl₃): δ 3.85 (s, 2H), 4.55 (s, 2H), 7.1 (m, 3H), 7.3 (t, 1H), 7.4 (d, 1H), 7.5-7.6 (m, 3H).
A37
[4-(4-Fluoro-phenyl)-2-(3'-methoxy-biphenyl-2-ylmethyl)-thiazol-5-yl]-acetic acid. Title compound was prepared from [2-(2-bromo-benzyl)-4-(4-fluoro-phenyl)-thiazol-5-yl]-acetic acid and 3-methoxyphenyl boronic acid according to RP8: LC/MS (an10p8) Rt 2.65 min, m/z 433 [M + H]+; 1H NMR (CDCl3): δ 3.76 (s, 3H), 3.81 (s, 2H), 4.43 (s, 2H), 6.8-6.9 (m, 2H), 7.1 (t, 1H), 7.3-7.5 (m, 7H), 7.7 (m, 2H).

A38
[2-(4'-Cyano-biphenyl-2-ylmethyl)-4-(4-fluoro-phenyl)-thiazol-5-yl]-acetic acid. Title compound was prepared from [2-(2-bromo-benzyl)-4-(4-fluoro-phenyl)-thiazol-5-yl]-acetic acid and 4-cyanophenyl boronic acid according to RP8: LC/MS (an10p8) Rt 2.47 min, m/z 428 [M + H]+; 1H NMR (CDCl3): δ 3.84 (s, 2H), 4.36 (s, 2H), 7.1 (t, 2H), 7.3-7.5 (m, 8H), 7.7 (d, 2H).

A39
[2-(3'-Acetlamino-biphenyl-2-ylmethyl)-4-(4-fluoro-phenyl)-thiazol-5-yl]-acetic acid. Title compound was prepared from [2-(2-bromo-benzyl)-4-(4-fluoro-phenyl)-thiazol-5-yl]-acetic acid and 3-acetamidobenzene boronic acid according to RP8: LC/MS (an10p8) Rt 2.18 min, m/z 460 [M + H]+; 1H NMR (CDCl3): δ 1.98 (s, 3H), 3.78 (s, 2H), 4.3 (s, 2H), 7.0-7.1 (m, 4H), 7.2-7.4 (m, 2H), 7.4 (m, 4H), 7.6 (m, 2H).

A40
[4-(4-Fluoro-phenyl)-2-(4'-methoxy-biphenyl-2-ylmethyl)-thiazol-5-yl]-acetic acid. Title compound was prepared from [2-(2-bromo-benzyl)-4-(4-fluoro-phenyl)-thiazol-5-yl]-acetic acid and 4-methoxyphenyl boronic acid according to RP8: LC/MS
(an10p8) Rt 2.60 min, m/z 433 [M + H]^+; ^1H NMR (CDCl₃): δ 3.82 (s, 2H), 3.84 (s, 3H), 4.37 (s, 2H), 6.9 (d, 2H), 7.1 (t, 2H), 7.2-7.3 (m, 5H), 7.4 (m, 1H), 7.5 (m, 2H).

**A41**

[4-(4-Fluoro-phenyl)-2-(2'-methoxy-biphenyl-2-ylmethyl)-thiazol-5-yl]-acetic acid. Title compound was prepared from [2-(2-bromo-benzyl)-4-(4-fluoro-phenyl)-thiazol-5-yl]-acetic acid and 2-methoxyphenyl boronic acid according to RP8: LC/MS (an10p8) Rt 2.55 min, m/z 433 [M + H]^+; ^1H NMR (CDCl₃): δ 3.71 (s, 3H), 3.81 (s, 2H), 4.3 (s, 2H), 6.9-7.0 (m, 2H), 7.1 (m, 3H), 7.2-7.4 (m, 4H), 7.4-7.5 (m, 3H).

**A42**

[2-(2-Benzo[1,3]dioxol-5-yl-benzyl)-4-(4-fluoro-phenyl)-thiazol-5-yl]-acetic acid. Title compound was prepared from [2-(2-Bromo-benzyl)-4-(4-fluoro-phenyl)-thiazol-5-yl]-acetic acid and 3,4-methylenedioxybenzene boronic acid according to RP8: LC/MS (an10p8) Rt 3.35 min, m/z 447 [M + H]^+; ^1H NMR (CDCl₃): δ 3.78 (s, 2H), 4.34 (s, 2H) 5.96 (s, 2H), 6.7 (m, 3H), 7.1 (t, 2H), 7.2-7.3 (m, 3H), 7.3 (d, 1H), 7.5 (t, 2H).

**A43**

[2-(3'-Cyano-biphenyl-2-ylmethyl)-4-(4-fluoro-phenyl)-thiazol-5-yl]-acetic acid. Title compound was prepared from [2-(2-bromo-benzyl)-4-(4-fluoro-phenyl)-thiazol-5-yl]-acetic acid and 3-cyanophenyl boronic acid according to RP8: LC/MS (an10p8) Rt 3.157 min, m/z 428 [M + H]^+; ^1H NMR (CDCl₃): δ 3.55 (s, 2H), 3.9 (s, 2H), 6.8 (m, 2H), 7.0 (m, 4H), 7.2-7.4 (m, 6H).

**A44**
[4-(4-Fluoro-phenyl)-2-(3′-trifluoromethoxy-biphenyl-2-ylmethyl]-thiazol-5-yl]-acetic acid. Title compound was prepared from [2-(2-bromo-benzyl)-4-(4-fluorophenyl)-thiazol-5-yl]-acetic acid and 3-trifluoromethoxyphenyl boronic acid according to RP8: LC/MS (an10p8) Rt 3.91 min, m/z 487 [M + H]^+; ^1H NMR (CDCl_3): δ 3.78 (s, 2H), 4.3 (s, 2H), 7.1 (t, 2H), 7.3 (m, 1H), 7.3 (t, 2H), 7.4-7.5 (m, 7H).

A45

[2-[[1-Acetyl-piperidin-4-yl]-phenyl-methyl]-4-(4-chloro-phenyl)-thiazol-5-yl]-acetic acid. Title compound was prepared from 3-bromo-4-(4-chloro-phenyl)-4-oxobutyric acid and 1-acetyl-4-phenyl-piperidine-4-carbothioic acid amide 2-(1-acetyl-piperidin-4-yl)-2-phenyl-thioacetamide according to RP6: LC/MS (an10p8) Rt 2.32 min, m/z 454.5 [M + H]^+.

A46

[4-(4-Chloro-phenyl)-2-(4-phenyl-piperidin-4-yl)-thiazol-5-yl]-acetic acid. Title compound, isolated as its HCl salt, was prepared by reacting [2-[[1-acetyl-piperidin-4-yl]-phenyl-methyl]-4-(4-chloro-phenyl)-thiazol-5-yl]-acetic acid with 4N aq. HCl at 95°C for 18 hours, followed by evaporation of solvent: LC/MS (an10p8) Rt 2.07 min, m/z 412.4 [M + H]^+.

A46

[4-(4-Chloro-phenyl)-2-(1-phenyl-cyclopropyl)-thiazol-5-yl]-acetic acid. Title compound was prepared from 3-bromo-4-(4-chloro-phenyl)-4-oxo-butyric acid and 1-phenyl-cyclopropanecarbothioic acid amide according to RP6: LC/MS (an10p8) Rt 3.57 min, m/z 369.8 [M + H]^+.

General synthetic route to imidazole analogs
**Intermediate-34**

3-Bromo-4-(4-fluorophenyl)-4-oxo-butyric acid methyl ester. 3-Bromo-4-(4-fluorophenyl)-4-oxobutyric acid (15 mmol) was dissolved in methanol (60 ml) and thionyl chloride (17 mmol) was added at 0 °C. After stirring at 80 °C for 2 h the solvent was evaporated. The residue was stripped with diethylether. The product was used directly in the next step: \(^1\)H NMR (CDCl3): \(\delta\) 3.00 (m, 1H), 3.33 (m, 1H), 3.67 (s, 3H), 5.44 (t, 1H), 7.15 (t, 2H), 8.06 (t, 2H).

**Intermediate-35**


**A48**

[2-Benzhydryl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-acetic acid. A suspension of 2,2-diphenylacetamidine (10 mmol) and potassium carbonate (38 mmol) in THF/H2O (150 mL/50 mL) was heated to reflux. 3-Bromo-4-(4-fluorophenyl)-4-oxo-butyric acid methyl ester (10 mmol) in THF (50 mL) was added slowly. The reaction mixture was refluxed for 16 h, and then concentrated. The residue was dissolved in water (10 mL) and extracted with CH2Cl2 (10 mL). The organic phase was dried (MgSO₄) and concentrated to produce [2-benzhydryl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-acetic acid methyl ester: LC/MS (an10p8): Rt 3.64 min, \(m/z\) 401 [M+H]⁺. The methyl ester in THF was added excess LiOH H₂O in water. The reaction was stirred at room temperature over night, 3% HCl was added until pH <1, and the mixture was extracted with CH₂Cl₂. The organic phase was dried (MgSO₄) and concentrated to
give the product was subject to hydrolysis with LiOH in water/THF.: LC/MS (an10n8): 
Rt 1.43 min, m/z 387 [M - H]+.

Biological Assays

Materials and Methods

Generation/origin of the cDNA Constructs. The coding sequence of the human 
CRTH2 receptor (genbank accession no NM_004778) was amplified by PCR from a 
human hippocampus cDNA library and inserted into the pcDNA3.1(+) expression 
vector (invitrogen) via 5’ HindIII and 3’ EcoRI. To generate a CRTH2-Renilla 
luciferase (CRTH2-Rluc) fusion protein, the CRTH2 coding sequence without a 
STOP codon and Rluc were amplified, fused in frame by PCR and subcloned into the 
pcDNA3.1(+)Zeo expression vector (invitrogen). Human β-arrestin2 (β-arrr2) N- 
terminally tagged with GFP² (βarr2-GFP²) and Renilla luciferase were purchased 
from BioSignal Packard Inc, (Montreal, Canada). The sequence identity of the 
construct was verified by restriction endonuclease digests and sequencing in both 
directions on an ABI Prism (Applied Biosystems, Foster City, CA).

Sequence ID CRTH2 (protein sequence):

MSANATLKPLCPILEQMSRLQHSHSTISYIDHAAVLLHGLASLLGLVEN 
GVILFVVGCRMRQTVTTWVLHALSDLASLSLPPFTTYFLAVGHSWELG 
TTFGLKHSSIFNFASGFLSSASISLDRCLQVRPVWAQNHRTVAAAHK 
VCLVNWALAVLVNVFVFRDTISSLRGRIMCYNVLLNPGPRDATCN 
SRQAALAVSKFLLAFIFYPLAIAASHHAAVLRLQHRGGRRRGRFVRLVAA 
VVAAFALCWLGPYHVFSLLEARAHANGLRPLVWRGLPFVTASLFSVAN 
PVLVLVTPCDMLRKLRLSRVTQESLGVDDSELGAGSSRRRTSSTARS 
ASPLALCSRPEEPGRFARLLGWLLGSCAASPQTGLNRALSSTSS

Sequence ID CRTH2 (nucleotide sequence):

atgctcgcc 
caacgcacc 
tctaacccac 
tctgcctcat 
cttgagcag 
atgacccgct 
tccagaccca 
cagcacaacc 
acacccgctc 
acatcgacca 
cegcgcctgc 
tctgcgagcct 
tctgcctgcc 
tgcagctgcct 
tcgcacccct 
tcctggctcc 
tctgccttc 
tctggcctcc 
tctgctctct 
ctgcacccc 
tctcctcact 
tgaggtcctc 
tctgggtgctg 
tctgcccttc 
tccctcact 
tctgccttc 
tcctcccctc 
tctgctgtgc 
tctgcagcct 
tctgcctgcc 
tctggggcgc 
tctgctagc 
tctgcgctgc 
tctgggcgtc 
tagcccagc 
tctgctctc 
tccctccca 
tctggtgcc 
tcctgacagc 
tctggtgctg 
tctgcctgcc
Cell Culture and Transfection. COS-7 cells were grown in Dulbecco's modified Eagle's medium (DMEM) 1885 supplemented with 10% fetal bovine serum, 100 units/ml penicillin, 1000 μg/ml streptomycin, and kept at 37°C in a 10% CO₂ atmosphere. HEK293 cells were maintained in Minimum Essential medium (MEM) supplemented with 10% (v/v) heat inactivated fetal calf serum (HIFCS), 2mM Glutamax™-I, 1% non essential amino acids (NEAA), 1% sodium pyruvate and 10 μg/ml gentamicin. For binding experiments, COS7 cells were transiently transfected with the CRTH2 receptor using a calcium phosphate-DNA coprecipitation method with the addition of chloroquine (as described by Holst et al., 2001+). To perform the functional Bioluminescence Resonance Energy Transfer (BRET) assays, a HEK293 cell clone stably expressing Barr2-GFP² and CRTH2-Rluc was generated (CRTH2-HEK293 cells).

Binding assay. 24h after transfection COS-7 cells were seeded into 96well plates at a density of 30,000 cells/well. Competition binding experiments on whole cells were then performed about 18-24 h later using 0.1 nM [³H]PGD2 (NEN, 172 Ci/mmol) in a binding buffer consisting of HBSS (GIBCO) and 10 mM HEPES. Competing ligands were diluted in DMSO which was kept constant at 1% (v/v) of the final incubation volume. Total and nonspecific binding were determined in the absence and presence
of 10 μM PGD2. Binding reactions were routinely conducted for 3 h at 4°C and terminated by 2 washes (100 μl each) with ice cold binding buffer. Radioactivity was determined by liquid scintillation counting in a TOPCOUNTER (Packard) following overnight incubation in Microscint 20. Stable HEK293 cells were seeded at a density of 30,000 cells/well 18-24 h prior to the binding assay which was performed essentially as described for COS7 cells above. Determinations were made in duplicates.

**BRET assay.** Functional BRET assays were performed on HEK293 cells stably expressing human CRTH2-Rluc and GFP²-β-arr2. Prior to their use in the BRET assay cells were detached and re-suspended in D-PBS with 1000 mg/L L-Glucose at a density of 2x10⁶ cells/mL. DeepBlueC™ was diluted to 50 μM in D-PBS with 1000 mg/L L-Glucose (light sensitive). 100 μL of cell suspension was transferred to wells in a 96-well microplate (white OptiPlate) and placed in the Mithras LB 940 instrument (BERTHOLD TECHNOLOGIES, Bad Wildbad, Germany). 12 μL/well agonist was then injected by injector 1 and 10 μL/well DeepBlueC™ was injected simultaneously by injector 2. Five seconds after the injections the light output from the well was measured sequentially at 400 nm and 515 nm, and the BRET signal (mBRET ratio) was calculated by the ratio of the fluorescence emitted by GFP²-β-arr2 (515 nm) over the light emitted by the receptor-Rluc (400 nm). Antagonists were added before placing the microplates into the Mithras LB 940 and allowed to incubate for 15 minutes prior to the addition of agonist and DeepBlueC™. Compounds were dissolved in DMSO and the final DMSO concentration was kept constant at 1% in the assay.

**Human eosinophil shape change assay.** Blood was sampled from healthy volunteers according to a protocol approved by the Ethics Committee of the University of Graz and processed as described previously (Bohm et al., 2004). Preparations of polymorphonuclear leukocytes (containing eosinophils and neutrophils) were prepared by dextran sedimentation of citrated whole blood and Histopaque gradients. The resulting cells were washed and resuspended in assay buffer (comprising PBS with Ca²⁺/Mg²⁺ supplemented with 0.1% BSA, 10 mM HEPES and 10 mM glucose, pH 7.4) at 5 x 10⁶ cells/mL. Cells were incubated with the antagonists or vehicle (PBS or DMSO) for 10 min at 37°C and then stimulated with various concentration of the agonists (PGD2 or eotaxin) for 4 min at 37°C. To stop the reaction, samples were transferred to ice and fixed with 250 μL of fixative
solution. Samples were immediately analyzed on a FACSCalibur flow cytometer (Becton Dickinson) and eosinophils were identified according to their autofluorescence in the FL-1 and FL-2 channels. Shape change responses were quantified as percentage of the maximal response to PGD2 or eotaxin in the absence of an antagonist.

**Materials**

Tissue culture media and reagents were purchased from the Gibco invitrogen corporation (Breda, Netherlands). PGD2 was obtained from Cayman and [3H]PGD2 from NEN.

**Data analysis**

Curve analysis was performed with the GraphPadPrism software 3.0 (Graphpad Prism Inc., San Diego, USA) and IC₅₀ values were calculated as a measure of the antagonistic potencies.

**References**


**Biological data:**

Compounds were tested in the receptor binding assay and the functional antagonist assay described below, and their IC₅₀ values were assessed. The compounds are grouped in three classes:

- **A:** IC₅₀ value lower than 0.5 µM
- **B:** IC₅₀ value between 0.5 µM and 5 µM
- **C:** IC₅₀ value higher than 5 µM

Tables 1 to 4 give the biological test results for the compounds synthesised above and for some additional compounds acquired from commercial sources.

The ability of the compounds above to inhibit prostaglandin D2 induced eosinophil shape change is demonstrated by the examples in Figure 1.
Table 1

<table>
<thead>
<tr>
<th></th>
<th>X</th>
<th>R1</th>
<th>R2</th>
<th>R3</th>
<th>Binding IC₅₀</th>
<th>Antag. IC₅₀</th>
</tr>
</thead>
<tbody>
<tr>
<td>A1</td>
<td>Bond</td>
<td>4-Cl</td>
<td>H</td>
<td>H</td>
<td>A</td>
<td>A</td>
</tr>
<tr>
<td>A4</td>
<td>Bond</td>
<td>4-F</td>
<td>H</td>
<td>H</td>
<td>A</td>
<td>A</td>
</tr>
<tr>
<td>A5</td>
<td>CH₂</td>
<td>4-Cl</td>
<td>H</td>
<td>H</td>
<td>A</td>
<td>B</td>
</tr>
<tr>
<td>A7</td>
<td>CH₂</td>
<td>4-F</td>
<td>4-Cl</td>
<td>H</td>
<td>A</td>
<td>A</td>
</tr>
<tr>
<td>A8</td>
<td>Bond</td>
<td>4-Cl</td>
<td>4-Cl</td>
<td>H</td>
<td>A</td>
<td>A</td>
</tr>
<tr>
<td>A9</td>
<td>CH₂</td>
<td>4-Cl</td>
<td>4-Cl</td>
<td>H</td>
<td>A</td>
<td>B</td>
</tr>
<tr>
<td>A10</td>
<td>Bond</td>
<td>4-F</td>
<td>4-Cl</td>
<td>H</td>
<td>A</td>
<td>A</td>
</tr>
<tr>
<td>A11</td>
<td>Bond</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>B</td>
<td>A</td>
</tr>
<tr>
<td>A12</td>
<td>Bond</td>
<td>4-MeO</td>
<td>H</td>
<td>H</td>
<td>A</td>
<td>B</td>
</tr>
<tr>
<td>A13</td>
<td>Bond</td>
<td>4-Cl</td>
<td>4-F</td>
<td>H</td>
<td>A</td>
<td>A</td>
</tr>
<tr>
<td>A14</td>
<td>Bond</td>
<td>4-F</td>
<td>4-F</td>
<td>4-F</td>
<td>A</td>
<td>A</td>
</tr>
<tr>
<td>A15</td>
<td>Bond</td>
<td>4-F</td>
<td>4-MeO</td>
<td>H</td>
<td>A</td>
<td>A</td>
</tr>
<tr>
<td>A16</td>
<td>Bond</td>
<td>4-Cl</td>
<td>4-MeO</td>
<td>H</td>
<td>A</td>
<td>A</td>
</tr>
<tr>
<td>A17</td>
<td>Bond</td>
<td>4-Cl</td>
<td>3,4-DiF</td>
<td>H</td>
<td>A</td>
<td>C</td>
</tr>
<tr>
<td>A18</td>
<td>Bond</td>
<td>4-F</td>
<td>3,4-DiF</td>
<td>H</td>
<td>A</td>
<td>A</td>
</tr>
<tr>
<td>A19</td>
<td>NHCO</td>
<td>4-F</td>
<td>H</td>
<td>4-CF₃</td>
<td>A</td>
<td>C</td>
</tr>
<tr>
<td>A20</td>
<td>Bond</td>
<td>4-F</td>
<td>4-MeO</td>
<td>4-MeO</td>
<td>A</td>
<td>A</td>
</tr>
<tr>
<td>A21</td>
<td>Bond</td>
<td>4-PhO</td>
<td>H</td>
<td>H</td>
<td>A</td>
<td>B</td>
</tr>
<tr>
<td>A22</td>
<td>Bond</td>
<td>4-F</td>
<td>4-OH</td>
<td>H</td>
<td>A</td>
<td>A</td>
</tr>
<tr>
<td>A23</td>
<td>Bond</td>
<td>3-F</td>
<td>H</td>
<td>H</td>
<td>A</td>
<td>A</td>
</tr>
<tr>
<td>A24</td>
<td>Bond</td>
<td>4-CF₃</td>
<td>H</td>
<td>H</td>
<td>B</td>
<td>C</td>
</tr>
<tr>
<td>A25</td>
<td>Bond</td>
<td>3,4-DiF</td>
<td>4-F</td>
<td>4-F</td>
<td>A</td>
<td>A</td>
</tr>
<tr>
<td>A26</td>
<td>Bond</td>
<td>3,4-DiF</td>
<td>H</td>
<td>Ph</td>
<td>A</td>
<td>A</td>
</tr>
<tr>
<td>A27</td>
<td>Bond</td>
<td>3-F</td>
<td>4-F</td>
<td>4-F</td>
<td>A</td>
<td>A</td>
</tr>
</tbody>
</table>
Table 2

<table>
<thead>
<tr>
<th></th>
<th>R1</th>
<th>R2</th>
<th>R3</th>
<th>Binding IC&lt;sub&gt;50&lt;/sub&gt;</th>
<th>Antag. IC&lt;sub&gt;50&lt;/sub&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>A28</td>
<td>4-Cl</td>
<td>H</td>
<td></td>
<td>A</td>
<td>B</td>
</tr>
<tr>
<td>A29</td>
<td>4-Cl</td>
<td>H</td>
<td></td>
<td>A</td>
<td></td>
</tr>
<tr>
<td>A30</td>
<td>4-F</td>
<td>4-MeO</td>
<td></td>
<td>A</td>
<td></td>
</tr>
<tr>
<td>A31</td>
<td>4-Cl</td>
<td>4-MeO</td>
<td></td>
<td>A</td>
<td>A</td>
</tr>
<tr>
<td>A32</td>
<td>4-Cl</td>
<td>H</td>
<td></td>
<td>B</td>
<td></td>
</tr>
<tr>
<td>A6</td>
<td>4-Cl</td>
<td>H</td>
<td>Et</td>
<td>A</td>
<td></td>
</tr>
</tbody>
</table>
Table 3

<table>
<thead>
<tr>
<th></th>
<th>X</th>
<th>R1</th>
<th>R2</th>
<th>Binding IC₅₀</th>
<th>Antag. IC₅₀</th>
</tr>
</thead>
<tbody>
<tr>
<td>A34</td>
<td>Bond</td>
<td>4-Cl</td>
<td>H</td>
<td>A</td>
<td>A</td>
</tr>
<tr>
<td>A35</td>
<td>O</td>
<td>4-Cl</td>
<td>H</td>
<td>B</td>
<td></td>
</tr>
<tr>
<td>A36</td>
<td>Bond</td>
<td>4-F</td>
<td>H</td>
<td>A</td>
<td>A</td>
</tr>
<tr>
<td>A37</td>
<td>Bond</td>
<td>4-F</td>
<td>3-MeO</td>
<td>A</td>
<td>A</td>
</tr>
<tr>
<td>A38</td>
<td>Bond</td>
<td>4-F</td>
<td>4-CN</td>
<td>A</td>
<td>A</td>
</tr>
<tr>
<td>A39</td>
<td>Bond</td>
<td>4-F</td>
<td>3-NHAc</td>
<td>B</td>
<td></td>
</tr>
<tr>
<td>A40</td>
<td>Bond</td>
<td>4-F</td>
<td>4-MeO</td>
<td>A</td>
<td>A</td>
</tr>
<tr>
<td>A41</td>
<td>Bond</td>
<td>4-F</td>
<td>2-MeO</td>
<td>A</td>
<td></td>
</tr>
<tr>
<td>A42</td>
<td>Bond</td>
<td>4-F</td>
<td>3,4-OCH₂O</td>
<td>A</td>
<td>A</td>
</tr>
<tr>
<td>A43</td>
<td>Bond</td>
<td>4-F</td>
<td>3-CN</td>
<td>A</td>
<td></td>
</tr>
<tr>
<td>A44</td>
<td>Bond</td>
<td>4-F</td>
<td>3-OCF₃</td>
<td>A</td>
<td></td>
</tr>
</tbody>
</table>
Table 4

<table>
<thead>
<tr>
<th></th>
<th>R1</th>
<th>R2</th>
<th>Binding IC&lt;sub&gt;50&lt;/sub&gt;</th>
<th>Antag. IC&lt;sub&gt;50&lt;/sub&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>A45</td>
<td>4-Cl</td>
<td><img src="image" alt="R2 structure" /></td>
<td>A</td>
<td>B</td>
</tr>
<tr>
<td>A46</td>
<td>4-Cl</td>
<td><img src="image" alt="R2 structure" /></td>
<td>B</td>
<td>C</td>
</tr>
</tbody>
</table>
Claims:
1. A compound of formula (I) or a salt, hydrate or solvate thereof:

![Chemical Structure](image)

wherein
\( X_1 \) is -S-, -O-, -N=N-; -NR\(_7\)-, -CR\(_7\)=CR\(_8\)-, -CR\(_7\)=N-, wherein \( R_7 \) and \( R_8 \) are independently hydrogen or \( C_1\text{-}C_3 \) alkyl;

\( A \) is a carboxyl group -COOH, or a carboxyl bioisostere;

rings \( \text{Ar}^2 \) and \( \text{Ar}^3 \) each independently represent a phenyl or 5- or 6-membered monocyclic heteroaryl ring, or a bicyclic ring system consisting of a 5- or 6-membered carbocyclic or heterocyclic ring which is benz-fused or fused to a 5- or 6-membered monocyclic heteroaryl ring, said ring or ring system being optionally substituted;

ring \( B \) is as defined for \( \text{Ar}^2 \) and \( \text{Ar}^3 \), or an optionally substituted N-pyrrolidinyl, N-piperidinyl or N-azepinyl ring;

\( s \) is 0 or 1;

\( L_1 \) represents a divalent radical of formula \(-(\text{Alk})_n^l\) and \( L_2 \) and \( L_4 \) each independently represents a divalent radical of formula \(-(\text{Alk})_m^l(Z)_n^l(\text{Alk})_p^l\) wherein

\( m, n \) and \( p \) are independently 0 or 1,

\( \text{Alk}^1 \) and \( \text{Alk}^2 \) are independently optionally substituted straight or branched chain \( C_1\text{-}C_3 \) alkylene or \( C_2\text{-}C_3 \) alkenylene radicals which may contain a compatible -O-, -S- or -NR- link wherein \( R \) is hydrogen or \( C_1\text{-}C_3 \) alkyl, and
Z is \(-\mathrm{O}\), \(-\mathrm{S}\), \(-\mathrm{C}(=\mathrm{O})\), \(-\mathrm{SO}_2\), \(-\mathrm{SO}\), \(-\mathrm{NR}\), \(-\mathrm{NRSO}_2\), \(-\mathrm{C}(=\mathrm{O})\mathrm{NR}\), \(-\mathrm{NRCNH}\), \(-\mathrm{NRC}(=\mathrm{NR})\mathrm{NH}\), wherein \(R\) is hydrogen or \(\mathrm{C}_1\mathrm{C}_3\) alkyl; or a divalent 5- or 6-membered monocyclic carbocyclic or heterocyclic radical;

\(L_3\) represents a divalent radical of formula \(-\mathrm{(Alk)}_3\)-\((Z)\)-\((\mathrm{Alk})_2\)- wherein \(m, n, p, \mathrm{Alk}^2\) and \(Z\) are as defined in relation to \(L_2\) and \(L_4\), and \(\mathrm{Alk}^3\) is an optionally substituted straight or branched chain \(\mathrm{C}_1\mathrm{C}_2\) alkyne or \(\mathrm{C}_1\mathrm{C}_2\) alkenylene radical which may contain a compatible \(-\mathrm{O}\), \(-\mathrm{S}\) or \(-\mathrm{NR}\) link wherein \(R\) is hydrogen or \(\mathrm{C}_1\mathrm{C}_3\) alkyl;

\(Q_1\) represents hydrogen or \((\mathrm{C}_1\mathrm{C}_6)\)alkyl;

\(Q_2\) represents

(i) \((\mathrm{C}_1\mathrm{C}_6)\)alkyl, \((\mathrm{C}_1\mathrm{C}_6)\)alkoxy, hydroxy, hydroxy\((\mathrm{C}_1\mathrm{C}_6)\)alkyl, nitrile \((\mathrm{-CN})\), phenyl, phenoxyl, monocyclic heteroaryl or heteroaryloxy with 5 or 6 ring atoms, \(-\mathrm{CONR}^4\mathrm{R}^8\), \(-\mathrm{NR}^8\mathrm{COR}^4\), \(-\mathrm{NR}^8\mathrm{SO}_2\mathrm{R}^4\) or \(-\mathrm{NR}^4\mathrm{CONR}^8\mathrm{R}^8\) wherein \(\mathrm{R}^4\) and \(\mathrm{R}^8\) are independently hydrogen or a \((\mathrm{C}_1\mathrm{C}_6)\)alkyl group, or \(\mathrm{R}^4\) and \(\mathrm{R}^8\) are linked to the same \(N\) atom to form a cyclic amino ring, and when \(Q\) is phenyl, phenoxyl or monocyclic heteroaryl or heteroaryloxy with 5 or 6 ring atoms the phenyl or heteroaryl ring is optionally substituted by any of \((\mathrm{C}_1\mathrm{C}_6)\)alkyl, \((\mathrm{C}_1\mathrm{C}_6)\)alkoxy, hydroxy, hydroxy\((\mathrm{C}_1\mathrm{C}_6)\)alkyl, \((\mathrm{C}_1\mathrm{C}_3)\)alkythio, halo, fully or partially fluorinated \((\mathrm{C}_1\mathrm{C}_3)\)alkyl, \((\mathrm{C}_1\mathrm{C}_3)\)alkoxy or \((\mathrm{C}_1\mathrm{C}_3)\)alkythio, trifluoromethylthio, nitro, nitrile \((\mathrm{-CN})\), \(-\mathrm{COOR}^4\), \(-\mathrm{COR}^4\), \(-\mathrm{OCOR}^4\), \(-\mathrm{SO}_2\mathrm{R}^4\), \(-\mathrm{CONR}^4\mathrm{R}^8\), \(-\mathrm{SO}_2\mathrm{NR}^4\mathrm{R}^8\), \(-\mathrm{NR}^4\mathrm{R}^8\), \(-\mathrm{NR}^4\mathrm{COR}^4\), \(-\mathrm{NR}^4\mathrm{COOR}^4\), \(-\mathrm{NR}^4\mathrm{SO}_2\mathrm{R}^4\) or \(-\mathrm{NR}^4\mathrm{CONR}^4\mathrm{R}^8\) wherein \(\mathrm{R}^4\) and \(\mathrm{R}^8\) are independently hydrogen or a \((\mathrm{C}_1\mathrm{C}_6)\)alkyl group, or \(\mathrm{R}^4\) and \(\mathrm{R}^8\) are linked to the same \(N\) atom to form a cyclic amino ring, or

(ii) hydrogen, but only when, in \(L_3\), \(Z\) represents an optionally substituted divalent 5- or 6-membered monocyclic carbocyclic or heterocyclic radical;

or \(Q_1\) and \(Q_2\) taken together with the carbon atom to which they are attached form a \(\mathrm{C}_3\mathrm{C}_6\) cycloalkyl ring or a monocyclic non-aromatic heterocyclic ring with 4-6 ring atoms;

and wherein the total length of \(L_2\) and \(L_3\) does not exceed that of an unbranched saturated chain of 10 carbon atoms.
2. A compound as claimed in claim 1 wherein (i) the length of each of L2, L3 and L4 does not exceed that of an unbranched saturated chain of 5 atoms and (ii) the total length of L2, L3 and L4 does not exceed that of an unbranched saturated chain of 7 atoms, and (iii) none of L1, L2, L3 and L4 includes more than two R substituents different from hydrogen.

3. A compound as claimed in claim 1 or claim 2 wherein L3 is a bond, Q₁ is hydrogen, and Q₂ is phenyl or monocyclic heteroaryl with 5 or 6 ring atoms optionally substituted by any of (C₁-C₆)alkyl, (C₁-C₆)alkoxy, hydroxy, hydroxy(C₁-C₆)alkyl, (C₁-C₆)alkythio, halo, fully or partially fluorinated (C₁-C₆)alkyl, (C₁-C₆)alkoxy or (C₁-C₆)alkythio, trifluoromethylthio, nitro, nitrile (-CN), -COOR, -COR², -OCOR², -SO₂R², -CONR²R³, -SO₂NR²R³, -NR²R³, -NR²COR², -NR²COOR², -NR²SO₂OR² or -NR²CONR²R³ wherein R² and R³ are independently hydrogen or a (C₁-C₆)alkyl group, or R² and R³ are linked to the same N atom to form a cyclic amino ring.

4. A compound as claimed in claim 1 or claim 2 wherein L3 is a bond, Q₁ is hydrogen, and Q₂ is phenyl, optionally substituted by any of fluoro, chloro, bromo, (C₁-C₆)alkyl, trifluoromethyl, (C₁-C₆)alkoxy, trifluoromethoxy, trifluoromethylthio, dimethylamino, cyano, (C₁-C₆alkyl)SO₂⁻, NH₂SO₂⁻, (C₁-C₆alkyl)NHSO₂⁻, (C₁-C₆alkyl)₂NSO₂⁻, -CONR²R³, and -NR²COR² wherein R² and R³ are independently hydrogen or a (C₁-C₆)alkyl group, or R² and R³ are linked to the same N atom to form a cyclic amino ring.

5. A compound as claimed in claim 1 or claim 2 wherein L3 is -CH₂⁻, -OH⁻, -SH⁻, -SO₂⁻, -NHC(=O)⁻, -CH=CH⁻, -NR₁⁻, or -NR₁CH₂⁻ wherein R₁⁻ is hydrogen or a C₁-C₆ alkyl.

6. A compound as claimed in claim 1 or claim 2 wherein Q₂ is hydrogen and L3 represents a divalent radical of formula -(Alk³)m⁻(Z)n-(Alk³)p⁻ wherein m is 0, n is 1, and Z is a phenylene radical optionally substituted by one or more of fluoro, chloro, bromo, (C₁-C₆)alkyl, trifluoromethyl, (C₁-C₆)alkoxy, trifluoromethoxy, trifluoromethylthio, dimethylamino, cyano, (C₁-C₆alkyl)SO₂⁻, NH₂SO₂⁻, (C₁-C₆alkyl)NHSO₂⁻, (C₁-C₆alkyl)₂NSO₂⁻, -CONR²R³, and -NR²COR² wherein R² and R³ are independently hydrogen or a (C₁-C₆)alkyl group, or R² and R³ are linked to the same N atom to form a cyclic amino ring.
7. A compound as claimed in claim 6 wherein Z is a 1, 2-phenylene radical optionally substituted by one or more of fluoro, chloro, bromo, (C₁-C₃)alkyl, trifluoromethyl, (C₁-C₃)alkoxy, trifluoromethoxy, trifluoromethylthio, dimethylamino, cyano, (C₁-C₃alkyl)SO₂⁻, NH₂SO₂⁻, (C₁-C₃alkyl)NHSO₂⁻, (C₁-C₃alkyl)₂NSO₂⁻, -CONR²R³, and -NR²COR¹ wherein R¹ and R² are independently hydrogen or a (C₁-C₆)alkyl group, or R¹ and R² are linked to the same N atom to form a cyclic amino ring.

8. A compound as claimed in claim 6 or claim 7 wherein Q₁ is hydrogen.

9. A compound as claimed in any of the preceding claims wherein X₁ is –S–.

10. A compound as claimed in any of the preceding claims wherein A is a carboxyl group –COOH.

11. A compound as claimed in any of claims 1 to 9 wherein A is a carboxyl bioisostere selected from -SO₂NHR and -P(=O)(OH)(OR) wherein R is hydrogen methyl or ethyl, -SO₂OH, -P(=O)(OH)(NH₂), -C(=O)NHCN and groups of formulae:

```
  N  N
  O
  *  O
```

12. A compound as claimed in any of the preceding claims wherein L₁ represents a bond, –CR₁₁R₁₂”, “–CH₂CR₁₁R₁₂”, “–OCR₁₁R₁₂”, “–SCR₁₁R₁₂”, “–NR₁₁CH₂” or “–NR₁₁” wherein R₁₁ and R₁₂ are independently hydrogen or C₁-C₃ alkyl, the bond marked with an asterisk being the one connected to the ring containing X¹.

13. A compound as claimed in any of claims 1 to 11 wherein L₁ represents –CH₂- or –CH(CH₃)-.

14. A compound as claimed in any of the preceding claims wherein Ar³ is phenyl, thiethyl, naphthyl or 2-, 3- or 4-pyridyl, any of which is optionally substituted.

15. A compound as claimed in claim 14 wherein optional substituents in Ar³ are selected from fluoro, chloro, bromo, (C₁-C₃)alkyl, trifluoromethyl, (C₁-C₃)alkoxy,
trifluoromethoxy, trifluoromethylthio, dimethylamino, cyano, (C₁-C₃alkyl)SO₂⁻,
NH₂SO₂⁻, (C₁-C₃alkyl)NHSO₂⁻, (C₁-C₃alkyl)₂NSO₂⁻, -CONRᴬRᴮ, and -NRᴮCORᴬ
wherein Rᴬ and Rᴮ are independently hydrogen or a (C₁-C₆)alkyl group, or Rᴬ and Rᴮ
are linked to the same N atom to form a cyclic amino ring.

16. A compound as claimed in any of the preceding claims wherein L₂ is a bond
and Ar² is an optionally substituted phenyl, thiényl, furanyl, pyrrolyl or pyridyl ring.

17. A compound as claimed in claim 16 wherein optional substituents in Ar² are
selected from fluoro, chloro, bromo, (C₁-C₃)alkyl, trifluoromethyl, (C₁-C₃)alkoxy,
trifluoromethoxy, trifluoromethylthio, dimethylamino, cyano, (C₁-C₃alkyl)SO₂⁻,
NH₂SO₂⁻, (C₁-C₃alkyl)NHSO₂⁻, (C₁-C₃alkyl)₂NSO₂⁻, -CONRᴬRᴮ, and -NRᴮCORᴬ
wherein Rᴬ and Rᴮ are independently hydrogen or a (C₁-C₆)alkyl group, or Rᴬ and Rᴮ
are linked to the same N atom to form a cyclic amino ring.

18. A compound as claimed in any of the preceding claims wherein s is 0.

19. A compound of formula (IA), or a salt, hydrate or solvate thereof:

```
                A₁
               /     \
              /       \  COOH
             /         /
            N-X₁-Ar³-H
               |     |
               |   /  |
               | /   |
               | /   |
               | /   |
               | /   |
               | /   |
```

wherein A₁ is hydrogen or methyl, X₁, Q₁, Ar³ and L₃ are as defined in claim 1, and
R₄ and R₅ independently represent hydrogen or one or more optional substituents.

20. A compound as claimed in claim 19 wherein A₁ is hydrogen.

21. A compound as claimed in claim 19 or claim 20 wherein Q₁ is hydrogen.

22. A compound as claimed in any of claims 19 to 21 wherein X₁ is -S-. 


23. A compound as claimed in any of claims 19 to 22 wherein Ar³ is optionally substituted phenyl.

24. A compound as claimed in any of claims 19 to 23 wherein L3 is a bond, -O-, -S-, or -NR- wherein R is hydrogen or C₁-C₃ alkyl.

25. A compound as claimed in claim 19 wherein A₁ is hydrogen, Q₁ is hydrogen, X₁ is -S-, Ar³ is optionally substituted phenyl and L3 is a bond.

26. A compound as claimed in any of claims 19 to 25 wherein optional substituents R₄ and R₅ and optional substituents in Ar³ are independently selected from fluoro, chloro, bromo, (C₁-C₃)alkyl, trifluoromethyl, (C₁-C₃)alkoxy, trifluoromethoxy, trifluoromethylthio, dimethylamino, cyano, (C₁-C₃alkyl)SO₂⁻, NH₂SO₂⁻, (C₁-C₃alkyl)NHSO₂⁻, (C₁-C₃alkyl)₂NSO₂⁻, -CONR⁻R⁻, and -NR⁻COR⁻ wherein R⁻ and R⁻ are independently hydrogen or a (C₁-C₆)alkyl group, or R⁻ and R⁻ are linked to the same N atom to form a cyclic amino ring.

27. A compound of formula (IB), or a salt, hydrate or solvate thereof:

\[
\text{(IB)}
\]

wherein A₁ is hydrogen or methyl, X₂ is a bond, -CH₂-, -O-, -S-, or -NR- wherein R is hydrogen or C₁-C₃ alkyl and X₁ and Ar³ are as defined in claim 1, and R₄ and R₅ independently represent hydrogen or one or more optional substituents.

28. A compound as claimed in claim 27 wherein A₁ is hydrogen.

29. A compound as claimed in claim 27 or claim 28 wherein X₁ is -S-.
30. A compound as claimed in any of claims 27 to 29 wherein \( \text{Ar}^3 \) is optionally substituted phenyl.

31. A compound as claimed in any of claims 27 to 30 wherein \( X_2 \) is \(-\text{CH}_2-\) or a bond.

32. A compound as claimed in any of claims 27 to 31 wherein optional substituents \( R_4 \) and \( R_5 \) and optional substituents in \( \text{Ar}^3 \) are independently selected from fluoro, chloro, bromo, \((\text{C}_1-\text{C}_3)\text{alkyl}, \text{trifluoromethyl, } (\text{C}_1-\text{C}_3)\text{alkoxy,}
\text{trifluoromethoxy, trifluoromethylthio, dimethylamino, cyano, } (\text{C}_1-\text{C}_3)\text{alkylSO}_2-,
\text{NH}_2\text{SO}_2- (\text{C}_1-\text{C}_3)\text{alkyl})\text{NHSO}_2-,(\text{C}_1-\text{C}_3)\text{alkyl})_2\text{NSO}_2-, -\text{CONR}^R\text{R}^S, \) and \(-\text{NR}^S\text{COR}^A\) wherein \( R^A \) and \( R^S \) are independently hydrogen or a \((\text{C}_1-\text{C}_6)\text{alkyl} \) group, or \( R^A \) and \( R^S \) are linked to the same \( N \) atom to form a cyclic amino ring.

33. A compound selected from the group consisting of

\[
\begin{align*}
\text{[2-benzhydryl-4-(4-chlorophenyl)-thiazol-5-yl]-acetic acid}, \\
\text{[2-benzhydryl-4-(4-fluoro-phenyl)-thiazol-5-yl]-acetic acid}, \\
\text{[2-[1-(4-chloro-phenyl)-2-phenyl-ethyl]-4-(4-fluoro-phenyl)-thiazol-5-yl]-acetic acid}, \\
\text{[4-(4-chloro-phenyl)-2-[(4-chloro-phenyl)-phenyl-methyl]-thiazol-5-yl]-acetic acid}, \\
\text{[2-[4-chloro-phenyl]-phenyl-methyl]-4-(4-fluoro-phenyl)-thiazol-5-yl]-acetic acid}, \\
\text{[2-[bis-(4-fluoro-phenyl)-methyl]-4-(4-fluoro-phenyl)-thiazol-5-yl]-acetic acid}, \\
\text{[4-(4-fluoro-phenyl)-2-[(4-methoxy-phenyl)-phenyl-methyl]-thiazol-5-yl]-acetic acid}, \\
\text{[4-(4-chloro-phenyl)-2-[(4-methoxy-phenyl)-phenyl-methyl]-thiazol-5-yl]-acetic acid}, \\
\text{[2-[3,4-difluoro-phenyl]-phenyl-methyl]-4-(4-fluoro-phenyl)-thiazol-5-yl]-acetic acid}, \\
\text{[2-[bis-(4-methoxy-phenyl)-methyl]-4-(4-fluoro-phenyl)-thiazol-5-yl]-acetic acid}, \\
\text{[2-benzhydryl-4-(3-fluoro-phenyl)-thiazol-5-yl]-acetic acid}, \\
\text{[2-[bis-(4-fluoro-phenyl)-methyl]-4-(3,4-difluoro-phenyl)-thiazol-5-yl]-acetic acid}, \\
\text{[2-benzhydryl-4-(3,4-difluoro-phenyl)-thiazol-5-yl]-acetic acid}, \\
\text{[2-[bis-(4-fluoro-phenyl)-methyl]-4-(3-fluoro-phenyl)-thiazol-5-yl]-acetic acid}, \\
\end{align*}
\]

and salts hydrates and solvates thereof.

34. A pharmaceutical composition comprising a compound as claimed in any of claims 1 to 33, together with a pharmaceutically acceptable carrier.
35. Use of a compound as claimed in any of claims 1 to 33 in the manufacture of a composition for the treatment of disease responsive to modulation of CRTH2 receptor activity.

36. A method of treatment of disease responsive to modulation of CRTH2 receptor activity comprising administering to a subject suffering such disease and effective amount of a compound as claimed in any of claims 1 to 33.

37. Use as claimed in claim 35 or a method as claimed in claim 36 wherein the disease is one associated with elevated levels of prostaglandin D2 (PGD2) or one or more active metabolites thereof.

38. Use or a method as claimed in claim 37 wherein the disease is an inflammatory, autoimmune, respiratory or allergy disease.

39. Use or method as claimed in claim 37 wherein the disease is selected from asthma, rhinitis, allergic airway syndrome, allergic rhinobronchitis, bronchitis, chronic obstructive pulmonary disease (COPD), nasal polypsis, sarcoidosis, farmer's lung, fibroid lung, cystic fibrosis, chronic cough, conjunctivitis, atopic dermatitis, Alzheimer's disease, amyotrophic lateral sclerosis, AIDS dementia complex, Huntington's disease, frontotemporal dementia, Lewy body dementia, vascular dementia, Guillain-Barre syndrome, chronic demyelinating polyradiculoneuropathy, multifocal motor neuropathy, plexopathy, multiple sclerosis, encephalomyelitis, panencephalitis, cerebellar degeneration and encephalomyelitis, CNS trauma, migraine, stroke, rheumatoid arthritis, ankylosing spondylitis, Behçet's Disease, bursitis, carpal tunnel syndrome, inflammatory bowel disease, Crohn's disease, ulcerative colitis, dermatomyositis, Ehlers-Danlos Syndrome (EDS), fibromyalgia, myofascial pain, osteoarthritis (OA), osteonecrosis, psoriatic arthritis, Reiter's syndrome (reactive arthritis), sarcoidosis, scleroderma, Sjogren's Syndrome, soft tissue disease, Still's Disease, tendinitis, polyarteritis Nodossa, Wegener's Granulomatosis, myositis (polymyositis dermatomyositis), gout, atherosclerosis, lupus erythematosus, systemic lupus erythematosus (SLE), type I diabetes, nephritic syndrome, glomerulonephritis, acute and chronic renal failure, eosinophilia fascitis, hyper IgE syndrome, sepsis, septic shock, ischemic reperfusion injury in the heart, allograft rejection after transplantations, and graft versus host disease.
40. Use or method as claimed in claim 37 wherein the disease selected from asthma, rhinitis, allergic airway syndrome, and allergic rhinobronchitis.